+

WO2018105799A1 - Cosmetic composition containing eichhornia crassipes extract as active ingredient - Google Patents

Cosmetic composition containing eichhornia crassipes extract as active ingredient Download PDF

Info

Publication number
WO2018105799A1
WO2018105799A1 PCT/KR2016/014621 KR2016014621W WO2018105799A1 WO 2018105799 A1 WO2018105799 A1 WO 2018105799A1 KR 2016014621 W KR2016014621 W KR 2016014621W WO 2018105799 A1 WO2018105799 A1 WO 2018105799A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
cosmetic composition
cream
skin
active ingredient
Prior art date
Application number
PCT/KR2016/014621
Other languages
French (fr)
Korean (ko)
Inventor
안인숙
Original Assignee
주식회사 진셀팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 진셀팜 filed Critical 주식회사 진셀팜
Priority to CN201680091346.4A priority Critical patent/CN110022854B/en
Publication of WO2018105799A1 publication Critical patent/WO2018105799A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Definitions

  • the present invention relates to a cosmetic composition containing the water hyacinth extract as an active ingredient.
  • Fine dust is an air pollutant containing harmful substances such as sulfurous acid gas, nitrogen oxides, ozone, and carbon monoxide, which occurs in automobiles and factories, and refers to a material that floats in the air for a long time.
  • Fine dust is invisible to small dust of less than 10 ⁇ m diameter, it is known that contains toxic substances such as sulfate, nitrate and the like. These fine dusts are produced by photochemical reactions of toxic substances or heavy metals from automobile fumes and factory chimneys in the air.In case of exposure to high concentrations of fine dust environment, cough, eye irritation, skin trouble, and inflammation of lung and airway cells May cause.
  • fine dust weakens the metabolism of the skin and lowers sebum control function may worsen itching and dryness. Impurities in the skin may not be properly removed, causing problems, and the fat balance on the skin surface may be disrupted, resulting in dryness and itching. In addition, fine dust may promote skin aging. The absorbed fine dust stimulates the pigment cells of the skin, causing black mushrooms and wrinkles.
  • Fine dust can be removed to some extent by cleansing, but the finer it is, the stronger the adsorptive force, so deeply penetrates into the pores can not be completely removed by normal cleansing.
  • an object of the present invention is to include a natural material as an active ingredient is excellent in biosafety, in particular, it provides a cosmetic composition excellent in fine dust adsorption power, including a water hyacinth extract It is.
  • a cosmetic composition for adsorption of fine dust comprising a water hyacinth extract as an active ingredient.
  • the water hyacinth extract may be a fermentation extract prepared by inoculating a fermentation strain.
  • the fermentation strain may be Lactobacillus kimchicus .
  • the extract is water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, acetone, petroleum ether, ethyl acetate, butyl acetate, trichloromethane, dichloromethane, chloroform, hexane and 1,3-butylene It may be extracted with one or more solvents selected from the group consisting of glycols.
  • the alcohol may be 65 to 75% concentration (v / v) of ethanol.
  • the cosmetic composition is composed of flexible cosmetics, nourishing cosmetics, moisture cream, nutrition cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and powder It may be formulated into one or more selected from the group.
  • Eichhornia Provided is a cosmetic composition for antioxidant, anti-inflammatory, skin moisturizing, or anti-wrinkle comprising crassipes ) extract as an active ingredient.
  • the cosmetic composition includes a hyacinth extract, that is, an extract derived from a natural plant as an active ingredient, the skin improvement effect is excellent, and in particular, the wrinkle improvement and the adsorption and removal effect of fine dust may be remarkably improved. .
  • the numerical range includes the numerical values defined in the range. All maximum numerical limits given throughout this specification include all lower numerical limits as if the lower numerical limits were clearly written. All minimum numerical limits given throughout this specification include all higher numerical limitations as if the higher numerical limit were clearly written. All numerical limitations given throughout this specification will include all better numerical ranges within the broader numerical range, as the narrower numerical limitations are clearly written.
  • a cosmetic composition comprising the hyacinth extract as an active ingredient.
  • the cosmetic composition may include an extract of natural origin as an active ingredient, as well as excellent skin improvement effect and biosafety, and may minimize skin irritation.
  • the cosmetic composition is excellent in antioxidant, anti-inflammatory, skin moisturizing effect, as well as skin wrinkle improvement and fine dust adsorption due to various active ingredients contained in water hyacinth.
  • Eichhornia ” crassipes ) is an aquatic plant of the Aquaticaceae, which can be harvested year round in the tropical and subtropical regions, and is an attribute plant that can be harvested more than eight times a year if the water temperature is maintained at 20 degrees or higher. It has the ability to absorb and remove nitrogen and phosphorus, which are the causes of underwater eutrophication, at 1,700 kg / ha and 300 kg / ha. Since the water hyacinth contains a variety of effective ingredients beneficial to a variety of skin can be used for the purpose of improving the skin and has an excellent effect of adsorbing fine dust in the air.
  • extract refers to a solvent in which the active ingredient contained in the extract is transferred by contacting the solvent and the extract raw material under specific conditions. All may be included regardless. For example, extracting a component dissolved in a solvent from a natural product using water or an organic solvent, and may include both a specific component of the natural product, such as obtained by extracting only a specific component such as oil.
  • the mixed extract may be extracted with one or more solvents selected from the group consisting of purified water, lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, and 1,3-butylene glycol, wherein the alcohol is 65 to 75% concentration (v / v) of ethanol.
  • solvents selected from the group consisting of purified water, lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, and 1,3-butylene glycol, wherein the alcohol is 65 to 75% concentration (v / v) of ethanol.
  • the active ingredient contained in the raw material may be different in the extraction ratio according to the polarity of the solvent, the ethanol has excellent selectivity in the extraction of physiologically active substances of the natural raw material to achieve the optimal skin improvement effect by the ethanol extraction Can be.
  • Water and ethanol are different in polarity, the active ingredient extracted according to each polarity can be different, and the concentration of the ethanol can be appropriately controlled so that the optimum skin improvement effect can be implemented. At this time, if the concentration of the ethanol is more than 75% may not be achieved a proper yield, if less than 65% may not be sufficiently extracted the effective ingredient showing the skin improvement effect.
  • the extract is washed with water, washed with water, dried and pulverized, and extracted with conventional methods such as reflux circulation extraction, pressure extraction, and ultrasonic extraction for about 1 to 24 hours with a solvent having a volume of 8 to 12 times the weight of the raw material. And may be prepared by filtration. In addition, the extract may be obtained in a powder state by an additional process such as distillation under reduced pressure or freeze drying.
  • the extract may also include an extract that has undergone conventional purification.
  • the extract may be subjected to various purification methods additionally performed, such as separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity, or affinity). It may comprise a fraction obtained through.
  • the cosmetic composition may include a fermentation extract prepared by inoculating a fermentation strain in the water hyacinth extract.
  • transformation refers to a process in which a specific microorganism uses an enzyme to decompose organic matter.
  • Raw materials that have undergone fermentation may have a significantly improved skin improvement effect than before fermentation due to changes in the properties of the active ingredient.
  • Metabolites contain various amino acids, organic acids, and antioxidants that are beneficial to the skin by fermentation, thereby promoting skin metabolism and imparting elasticity to the skin texture.
  • the active ingredient particles may be reduced in size by fermentation and decompose toxins such as heavy metals, thereby reducing side effects such as skin troubles and allergies and improving absorption.
  • the “fermented extract” may be prepared by inoculating fermented strains after the hyacinth extract is dried naturally or using a rotary pressure reducer and a lyophilizer, diluted to a certain concentration in a specific solvent.
  • the fermentation strain is Lactobacillus genus (Lactobacillus sp.), Pseudomonas in coarse (Monascus sp.), Bacterial genus bifidobacteria (Bifidobacterium sp . ), Prevotella sp . , Fusobacterium sp . ), And Eubacterium sp . Strain, and may be selected from the group consisting of the strains of the genus Lactobacillus.
  • the strains of the genus Lactobacillus Lactobacillus ( Lactobacillus kimchicus ), Lactobacillus pentosus ( Lactobacillus pentosus ), Lactobacillus brevis ( Lactobacillus brevis ), Lactobacillus plantarum ( Lactobacillus plantarum ), Lactobacillus casei (L) Or Lactobacillus acidophilus ( Lactobacillus acidophilus ), but may be preferably Lactobacillus kimchicus ( Lactobacillus kimchicus ).
  • the cosmetic composition is one or more selected from the group consisting of flexible cosmetics, nourishing cosmetics, moisture cream, nutrition cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and powder Can be formulated.
  • the cosmetic composition may be for wrinkle improvement or fine dust adsorption, supple cosmetics, astringent cosmetics, nourishing cosmetics, lotions, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, And it may be formulated with one or more selected from the group consisting of a powder.
  • the cosmetic composition may be appropriately blended with other ingredients within the range of not impairing the object according to the present invention in accordance with the type or purpose of use of the formulation other than the active ingredient in each formulation.
  • the cosmetic composition may be prepared according to the quality or function of the final product, such as fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, Commonly used in cosmetics or dermatology, such as ionic or nonionic emulsifiers, fillers, metal ion rod blockers, chelating agents, preservatives, blockers, wetting agents, essential oils, dyes, pigments, and hydrophilic or lipophilic active agents Supplement may be additionally included.
  • ionic or nonionic emulsifiers such as ionic or nonionic emulsifiers, fillers, metal ion rod blockers, chelating agents, preservatives, blockers, wetting agents, essential oils, dyes, pigments, and hydrophilic or lipophilic active agents Supplement may be additionally included.
  • the adjuvant and its mixing ratio are preferably selected appropriately so as not to affect the desirable properties of the cosmetic composition according to the present invention.
  • the water was washed with hyacinth, dried at room temperature and pulverized to obtain 100 g of coarse pulverized product.
  • 100 g of each pulverized product was immersed in 10-fold volume of 70% concentration (v / v) ethanol and extracted under reflux for 12 hours at a temperature of 80 ° C.
  • the extract was filtered with 250 mesh and 0.5 ⁇ m filter paper and extracted three times in the same manner for the remaining raw materials and then cooled at room temperature.
  • the extract was concentrated under reduced pressure at 20 ° C. and lyophilized to give a solid.
  • Bifidobacterium bifiderum Bifidobacterium bifidum
  • the fermented extract was filtered with 500 mesh and 0.2 ⁇ m filter paper to obtain a hyacinth fermented extract and used as a sample of Example 2.
  • Example 3 A sample of Example 3 was obtained in the same manner as in Example 2, except that Lactobacillus plantarum was used as the fermentation strain.
  • Example 4 A sample of Example 4 was obtained in the same manner as in Example 2 except for using Lactobacillus kimchicus as a fermentation strain.
  • Example 1 The extracts of Example 1 were suspended at concentrations of 0, 20, 40, 60, 80, and 100 ug / mL, and the fermentation extracts of Examples 2 to 4 were prepared at concentrations of 0.001, 0.005, 0.01, 0.05, and 0.1% ( w / w), respectively.
  • Cytotoxicity was performed by modifying Mosmann's method of measuring cell viability using MTT ⁇ 3- (4,5-dimethylthiazol-2-yl) -2-5-diphenyltetrazolium bromide ⁇ reagent.
  • Fibroblasts (HDF), melanocytes (B16F10), and keratinocytes (HaCaT) were each dispensed in 96-well plates at a concentration of 1 ⁇ 10 4 cells / well and incubated at 37 ° C., 5% CO 2 for 48 hours. It was.
  • MTT was dissolved in PBS at 5 mg / mL, 50 L was added, and incubated for 48 hours at 37 ° C. and 5% CO 2 . 100 L of DMSO (dimethyl sulfoxide) was added per well, stirred for 10 minutes, and the absorbance was measured at 540 nm.
  • DMSO dimethyl sulfoxide
  • the free radical scavenging activity was measured using the free radical DPPH (1, 1-diphenyl-2-picryl hydrazyl).
  • the extract was evaluated to have higher free radical scavenging activity than ⁇ -tocopherol and BHT, which are well known in the art. Therefore, the decomposition of free radicals may be promoted by the extract, and the results suggest that skin aging and skin condition improvement effect by the antioxidant activity is excellent.
  • Raw 264.7 cells were incubated in 96 well plates at a concentration of 1 ⁇ 10 4 cells / well. The medium was exchanged with fresh medium and the cells were incubated for 24 hours after treatment of the extract.
  • the extract was diluted with dimethylsulfoxide (DMSO, Sigma-Aldrich, USA) to a maximum concentration of 20 ⁇ M based on the final concentration, DMSO was used as a blank test (negative control). The experiment was repeated three times to secure the reliability.
  • DMSO dimethylsulfoxide
  • the experiment was performed under the same cell line and the same cell culture conditions as the WST-1 assay, a cell activity measurement test.
  • the cultured Raw 264.7 cells were washed once with a solution of Phosphate Buffered Saline (PBS; sodium chloride 137 mM, phosphate buffer 10 mM, potassium chloride 2.7 mM, all from Biopure, Canada) and then harvested Raw 264.7 cells. Suspended in 15 mL PBS solution, 15 ⁇ L of 20 mM 2 ', 7'-Dichlorofluorescein diacetate was added and incubated for 1 hour.
  • PBS Phosphate Buffered Saline
  • the amount of reactive oxygen species was evaluated by measuring the fluorescence at 485 nm excitation / 535 nm emission using a fluorescence microplate reader.
  • the extract treated in the reactive oxygen species measurement test for the sample concentration was used as the sample concentration set by measuring the cell activity.
  • DMSO DMSO was used instead of the sample material.
  • ascorbic acid Sigma-Aldrich
  • DMSO was diluted to 100 mg / mL in DMSO and used at a concentration of 100 ⁇ g / mL.
  • Example 1 0 48.2 61.5
  • Example 2 0 51.3 65.8
  • Example 3 0 53.7 67.4
  • Example 4 0 57.2 70.1
  • the extract was evaluated to equal levels of ascorbic acid and free radical scavenging activity well known in the art. That is, the results suggest that the active oxygen species removal ability of Examples 1 to 4 is excellent, and the antioxidant effect due to free radical scavenging activity is excellent.
  • NF-kB transcription inhibition effect was measured by NF-kB reporter assay.
  • INOS, COX-2, IFN- ⁇ , TNF- ⁇ , etc. induced by LPS are expressed by the transcription factor NF-kB.
  • the NF-kB is inactivated in complex with IkB in the cytoplasm.
  • I-kB- ⁇ is phosphorylated by I-kB- ⁇ kinase
  • the bound complex is decomposed and activated by NF-kB to move into the nucleus.
  • )do Induces expression of target gene of NF-kB and causes inflammatory action.
  • TRIF which acts on inflammatory diseases such as multiple sclerosis, is a TIP-domain with an interferon- ⁇ -inducing receptor, which is a receptor that responds to the activity of TLRs (toll-like-receptors). It recognizes the specific composition of activating the immune response to the antigen. The receptor recognizes well-conserved pathogenic patterns and activates signals to stimulate the release of inflammatory cytokines.
  • IRF-3 interferon stimulatory gene 3
  • IRF-3 is a transcription activating factor induced by interferon ⁇ / ⁇ stimulation and binds to the interferon stimulation sequence (ISRE) in the transcriptional regulatory region of interferon-induced genes and activates its transcription.
  • NF-kB depending on the presence of receptor molecules (MyD88 and TRIF), such as ⁇ -galactosidase, using the PEI method in 12-well plates according to the manufacturer's protocol (Jin et al., 2009).
  • 1 ⁇ g of plasmid containing each of Luc or TRIF was transfected into HEK293 (1 ⁇ 10 6 cells / ml) cells. After culturing for 24 hours, LPS (100 ng / ml) and the extract were treated, and after 24 hours, luciferase assays were used to measure NF-kB activity and IRF-3 activity.
  • the luciferase assay was performed using a luciferase assay system (Promega Co., USA) reported in the manufacturer's protocol (Jung et al., 2009), and the analysis results are shown in Table 3 below.
  • the treatment of the extract significantly reduced the activity of NF-kB and IRF-3.
  • the results suggest that the extract effectively inhibits the transcription of NF-kB, thereby inhibiting or alleviating inflammation and preventing and improving inflammatory diseases.
  • the anti-inflammatory activity of the extract was evaluated by analyzing the expression levels of TNF- ⁇ , iNOS, and COX-2.
  • RNA was prepared from LPS treated RAW264.7 cells. The method was prepared using Trizol Reagent (Gibco BRL) as described by Lee et al., 2008. All RNA was used after storage at -70 °C. Semi-quantitative RT reaction was performed using MuLV reverse transcriptase.
  • RNA (1 ⁇ g) was incubated with oligo-dT15 at 70 ° C. for 5 minutes and mixed with 5 ⁇ first strand buffer, 10 mM dNTPs and 0.1 M DTT. The reaction mixture was further incubated at 37 ° C. for 5 minutes and incubated for 60 minutes after the addition of MuLV reverse transcriptase (2 U). The reaction was terminated by incubating at 70 ° C. for 10 minutes. RNase H was added to remove all RNA and PCR reactions were performed (conditions: 2 ⁇ L cDNA, 4 ⁇ M 5 ′ and 3 ′ primers, 10 ⁇ buffer (10 mM Tris-HCl, pH 8.3; 50 mM KCl and 0.1).
  • PCR reaction was denatured at 94 ° C. for 30 seconds and after annealing at 55 to 60 ° C. for 30 seconds, 72 It superposed
  • MRNA expression level measurement results according to the extract treatment is shown in Table 5.
  • MRNA analysis of RAW264.7 cells resulted in increased expression of TNF- ⁇ , iNOS, and COX-2 by the addition of LPS.
  • the expression of TNF- ⁇ , iNOS, and COX-2 induced by LPS decreased in a concentration-dependent manner when the extract was treated.
  • the sample powders obtained in Examples 1 to 4 were suspended in purified water, diluted by concentration, and the skin moisturizing effect was evaluated.
  • the expression level of the HAS2 gene and AQP3 gene involved in skin moisturization in human keratinocytes was measured at the mRNA level.
  • HaCaT Human keratinocytes
  • Keratinocytes were dispensed into 96 well plates at a concentration of 1 ⁇ 10 6 cells / mL and incubated for 24 hours. After exchange with DMEM free medium was treated extracts of Examples 1 to 4 diluted by concentration and incubated for 24 hours.
  • RNA extracted RNA was extracted.
  • PBS cold phosphate buffer
  • Trizol TM reagent Trizol TM reagent, Life Technologies, Inc.
  • Gene expression changes were measured by qRT-PCR (quantitative real time PCR), which binds the fluorescent material to the DNA product amplified in the polymerase chain reaction (PCR) and continuously detects the fluorescent material.
  • qRT-PCR quantitative real time PCR
  • fluorescence values emitted by PCR products were measured through SYBR green I (Invitrogen).
  • a reaction solution was prepared by mixing 0.2 ⁇ M primer, 50 mM KCl, 20 mM Tris / HCl pH 8.4, 0.8 mM dNTP, 0.5U Extaq DNA polymerase, 3 mM MgCl 2 , and 1 ⁇ SYBR green.
  • the Ct value is the number of cycles when the amount of fluorescence generated by the PCR product (the number of amplified PCR products) reaches a predetermined reference value above the basic value. Primer sequences used in the experiment are shown in Table 6 below.
  • HAS2 and AQP3 mRNA expression level measurement results are shown in Table 7 below, mRNA expression level was increased concentration-dependently according to the treatment of the extract. The higher the HAS2 and AQP3 expression promoting ability can be evaluated as an excellent skin moisturizing effect.
  • Example 1 0 ⁇ g / mL 1.00 1.00 50 ⁇ g / mL 1.23 1.07 100 ⁇ g / mL 1.86 1.24
  • Example 2 0 ⁇ g / mL 1.00 1.00 50 ⁇ g / mL 1.47 1.16 100 ⁇ g / mL 2.21 1.37
  • Example 3 0 ⁇ g / mL 1.00 1.00 50 ⁇ g / mL 1.61 1.26 100 ⁇ g / mL 2.43 1.48
  • Example 4 0 ⁇ g / mL 1.00 1.00 50 ⁇ g / mL 1.76 1.35 100 ⁇ g / mL 2.86 1.54
  • Human dermal fibroblasts were dispensed in 96 well plates at a concentration of 1.0 ⁇ 10 4 cells / mL, and cultured for 3 days at 37 ° C., 5% CO 2 , and humidified conditions.
  • the medium was exchanged with DMEM (Dulbecco's Modified Eagle's Medium, manufactured by Sigma), and incubated after treating the extracts 1 to 4 at a concentration of 50 mg / L. Purified water was added without treating the extract as a control.
  • DMEM Dulbecco's Modified Eagle's Medium, manufactured by Sigma
  • the culture medium was collected, and the concentration of type I collagen secreted in the culture medium was quantified by an enzyme-linked immunoassay (Procollagen type I c-peptide EIA Kit; manufactured by Takara Bio Co., Ltd.).
  • the amount of collagen in each test sample culture was calculated based on the type I collagen amount of the control group (100%), and the measurement results are shown in Table 8 below.
  • the sample powders obtained in Examples 1 to 4 were suspended in purified water, diluted by concentration, and the effect of improving wrinkles was evaluated.
  • the extracts of Examples 1 to 4 diluted by concentration were treated to human dermal fibroblasts and cultured for 24 hours to determine the degree of collagen expression change.
  • Gene expression changes were measured by qRT-PCR (quantitative real time PCR), which binds the fluorescent material to the DNA product amplified in the polymerase chain reaction (PCR) and continuously detects the fluorescent material.
  • qRT-PCR quantitative real time PCR
  • the Ct value is the number of cycles when the amount of fluorescence generated by the PCR product (the number of amplified PCR products) reaches a predetermined reference value above the basic value. Primer sequences used in the experiment are shown in Table 9 below.
  • the extract can promote the production of collagen and thereby improve the skin elasticity and wrinkles bar use of skin care It can be used as
  • Example 1 0% (w / w) 1.00 1.00 0.01% (w / w) 1.82 0.79 0.1% (w / w) 2.62 0.45
  • Example 2 0% (w / w) 1.00 1.00 0.01% (w / w) 1.89 0.77 0.1% (w / w) 2.95 0.42
  • Example 3 0% (w / w) 1.00 1.00 0.01% (w / w) 2.07 0.79 0.1% (w / w) 3.09 0.40
  • Example 4 0% (w / w) 1.00 1.00 0.01% (w / w) 1.95 0.72 0.1% (w / w) 3.16 0.37
  • the lotion formulated with extracts of Examples 1 to 4 was applied to 50 women aged 40 to 60 years every morning and evening twice a month for 1 month to evaluate the degree of wrinkle improvement.
  • the cream formulated with the extracts of Examples 1 to 4 significantly reduced the total number of wrinkles, wrinkle area, wrinkle length, skin wrinkle parameters, the result is that the extract improves skin wrinkles and skin beauty It can be used as a purpose.
  • the measured value was expressed as the average of three times except the maximum value and minimum value of Ra. The higher the measured value means a lot of skin wrinkles, the results are shown in Table 12.
  • the cream containing the hyacinth lactobacillus kimchicus fermented extract (Example 4) has the most excellent skin texture improvement effect, when the cream of the control group does not contain the hyacinth extract, the skin texture improvement effect is significantly insufficient. It was.
  • PAH polycyclic aromatic hydrocarbons
  • Examples 1 to 4 extracts were treated with the specimens at a concentration of 50 mg / L and reacted for 3 hours, and the control group was coated with PBS and reacted for 3 hours.
  • Example 1 Example 2
  • Example 3 Example 4 naphthalene 7.1 5.5 4.7 3.4 Acenaphthylene 10.5 8.2 6.4 5.1 Fluorene 9.3 7.3 5.1 2.8 Fluoranthene 9.3 6.9 4.5 3.2 Pyren 3.6 2.5 1.9 1.8 Krissen 4.9 3.9 2.3 1.3 Benzopyrene 3.1 2.7 2.2 1.3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides a cosmetic composition containing an Eichhornia crassipes extract as an active ingredient for fine dust adsorption.

Description

부레옥잠 추출물을 유효성분으로 함유하는 화장료 조성물Cosmetic composition containing hyacinth extract as an active ingredient
본 발명은 부레옥잠 추출물을 유효성분으로 함유하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing the water hyacinth extract as an active ingredient.
미세먼지는 아황산가스, 질소 산화물, 오존 및 일산화 탄소 등의 유해 물질을 포함하는 대기오염 물질로서 자동차 및 공장 등에서 발생하며, 대기 중 장기간 떠다니는 물질을 의미한다.Fine dust is an air pollutant containing harmful substances such as sulfurous acid gas, nitrogen oxides, ozone, and carbon monoxide, which occurs in automobiles and factories, and refers to a material that floats in the air for a long time.
급속한 산업화, 자동자 배출가스, 중국으로부터 이동해온 공기덩어리에 의한 중금속 가루 및 미세먼지 등 외부 오염물이 사람들의 피부를 오염시키며, 피부 노화 및 트러블 발생의 큰 원인으로 손꼽히고 있다.External industrial contaminants such as rapid industrialization, automotive exhaust gas, heavy metal powder and fine dust from air masses from China are contaminating people's skin and are considered as a major cause of skin aging and trouble.
미세먼지는 눈에 보이지 않는 지름 10㎛ 이하의 작은 먼지를 가리키며, 황산염, 질산염 등과 같은 독성 물질이 포함되어 있는 것으로 알려져 있다. 이러한 미세먼지는 자동차 매연과 공장 굴뚝에서 나온 유독물질 또는 중금속 등이 대기 중에서 광화학 반응을 일으켜 만들어지며, 고농도의 미세먼지 환경에 노출되는 경우, 기침, 안구 따가움, 피부 트러블, 폐·기도 세포에 염증을 유발할 수 있다.Fine dust is invisible to small dust of less than 10㎛ diameter, it is known that contains toxic substances such as sulfate, nitrate and the like. These fine dusts are produced by photochemical reactions of toxic substances or heavy metals from automobile fumes and factory chimneys in the air.In case of exposure to high concentrations of fine dust environment, cough, eye irritation, skin trouble, and inflammation of lung and airway cells May cause.
또한, 미세먼지는 피부의 신진대사를 약화시키고 피지조절 기능을 저하시키므로 가려움증 및 건조증을 악화시킬 수 있다. 피부 내 노폐물이 제대로 제거되지 않아 트러블이 유발되고, 피부 표면의 지방질 균형이 붕괴되어 건조증 및 가려움증이 야기될 수 있다. 또한, 미세먼지는 피부 노화를 촉진할 수 있다. 흡수된 미세먼지는 피부의 색소세포를 자극해 검버섯 등을 유발하고 주름을 발생시킨다.In addition, fine dust weakens the metabolism of the skin and lowers sebum control function may worsen itching and dryness. Impurities in the skin may not be properly removed, causing problems, and the fat balance on the skin surface may be disrupted, resulting in dryness and itching. In addition, fine dust may promote skin aging. The absorbed fine dust stimulates the pigment cells of the skin, causing black mushrooms and wrinkles.
미세먼지는 클렌징으로 어느 정도 제거할 수 있지만, 미세할수록 흡착력이 강하기 때문에 모공에 깊숙이 스며들어 일반 클렌징으로는 완벽하게 제거될 수 없다.Fine dust can be removed to some extent by cleansing, but the finer it is, the stronger the adsorptive force, so deeply penetrates into the pores can not be completely removed by normal cleansing.
한편, 화장품 업계에서는 여러 화학물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 제품이 다수 개발되고 있다. 천연 재료는 피부에 부작용이 적을 뿐 아니라, 최근 천연 재료를 이용한 화장품에 대한 소비자들의 호응이 높아짐에 따라 화장품 원료로서 개발가치가 한층 늘어나고 있다. Meanwhile, in the cosmetic industry, many products using natural products have been developed to reduce skin irritation caused by various chemicals. Natural ingredients have less side effects on the skin, and as the consumer's response to cosmetics using natural ingredients has increased recently, the development value of cosmetics as a raw material for cosmetics is increasing.
따라서, 천연 재료 기반의 추출물을 포함하여 피부 안정성을 제고하면서도, 미세먼지의 흡착력이 우수한 화장료 조성물의 개발이 요구되고 있다.Therefore, while improving skin stability, including extracts based on natural materials, the development of a cosmetic composition excellent in adsorption power of fine dust is required.
본 발명은 전술한 종래 기술의 문제점을 해결하기 위한 것으로, 본 발명의 목적은 천연 재료를 유효성분으로 포함하여 생체 안전성이 우수하며, 특히, 부레옥잠 추출물을 포함하여 미세먼지 흡착력이 우수한 화장료 조성물을 제공하는 것이다.The present invention is to solve the above-mentioned problems of the prior art, an object of the present invention is to include a natural material as an active ingredient is excellent in biosafety, in particular, it provides a cosmetic composition excellent in fine dust adsorption power, including a water hyacinth extract It is.
본 발명의 일 측면에 따르면, 부레옥잠 추출물을 유효성분으로 포함하는 미세먼지 흡착용 화장료 조성물이 제공된다.According to one aspect of the present invention, there is provided a cosmetic composition for adsorption of fine dust comprising a water hyacinth extract as an active ingredient.
일 실시예에 있어서, 상기 부레옥잠 추출물은 발효 균주를 접종하여 제조된 발효 추출물일 수 있다.In one embodiment, the water hyacinth extract may be a fermentation extract prepared by inoculating a fermentation strain.
일 실시예에 있어서, 상기 발효 균주는 락토바실러스 김치쿠스(Lactobacillus kimchicus)일 수 있다.In one embodiment, the fermentation strain may be Lactobacillus kimchicus .
일 실시예에 있어서, 상기 추출물은 물, 탄소수 1 내지 4개의 무수 또는 함수 저급 알코올, 아세톤, 석유에테르, 에틸아세테이트, 부틸아세테이트, 트리클로로메탄, 디클로로메탄, 클로로포름, 헥산 및 1,3-부틸렌글리콜로 구성된 군으로부터 선택되는 하나 이상의 용매로 추출될 수 있다.In one embodiment, the extract is water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, acetone, petroleum ether, ethyl acetate, butyl acetate, trichloromethane, dichloromethane, chloroform, hexane and 1,3-butylene It may be extracted with one or more solvents selected from the group consisting of glycols.
일 실시예에 있어서, 상기 알코올은 65 내지 75% 농도(v/v)의 에탄올일 수 있다. In one embodiment, the alcohol may be 65 to 75% concentration (v / v) of ethanol.
일 실시예에 있어서, 상기 화장료 조성물은 유연화장수, 영양화장수, 수분크림, 영양크림, 마사지크림, 에센스, 앰플, 젤, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있다.In one embodiment, the cosmetic composition is composed of flexible cosmetics, nourishing cosmetics, moisture cream, nutrition cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and powder It may be formulated into one or more selected from the group.
본 발명의 다른 측면에 따르면, 부레옥잠(Eichhornia crassipes) 추출물을 유효성분으로 포함하는 항산화, 항염증, 피부 보습, 또는 주름 개선용 화장료 조성물이 제공된다.According to another aspect of the invention, Eichhornia Provided is a cosmetic composition for antioxidant, anti-inflammatory, skin moisturizing, or anti-wrinkle comprising crassipes ) extract as an active ingredient.
본 발명에 따르면, 상기 화장료 조성물은 부레옥잠 추출물, 즉, 천연 식물에 유래의 추출물을 유효성분으로 포함하므로 피부 개선 효과가 우수하며 특히, 주름개선 및 미세먼지의 흡착 및 제거 효과가 현저히 개선될 수 있다.According to the present invention, since the cosmetic composition includes a hyacinth extract, that is, an extract derived from a natural plant as an active ingredient, the skin improvement effect is excellent, and in particular, the wrinkle improvement and the adsorption and removal effect of fine dust may be remarkably improved. .
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.It is to be understood that the effects of the present invention are not limited to the above effects, and include all effects deduced from the configuration of the invention described in the detailed description or claims of the present invention.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.The terminology used herein is to select general terms that are currently widely used as possible in consideration of the functions in the present invention, but may vary according to the intention or precedent of the person skilled in the art, the emergence of new technologies and the like. In addition, in certain cases, there is also a term arbitrarily selected by the applicant, in which case the meaning will be described in detail in the description of the invention. Therefore, the terms used in the present invention should be defined based on the meanings of the terms and the contents throughout the present invention, rather than the names of the simple terms.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다. Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art. Terms such as those defined in the commonly used dictionaries should be construed as having meanings consistent with the meanings in the context of the related art, and are not construed in ideal or excessively formal meanings unless expressly defined in this application. Do not.
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.The numerical range includes the numerical values defined in the range. All maximum numerical limits given throughout this specification include all lower numerical limits as if the lower numerical limits were clearly written. All minimum numerical limits given throughout this specification include all higher numerical limitations as if the higher numerical limit were clearly written. All numerical limitations given throughout this specification will include all better numerical ranges within the broader numerical range, as the narrower numerical limitations are clearly written.
이하, 본 발명의 실시예를 상세히 기술하나, 하기 실시예에 의해 본 발명이 한정되지 아니함은 자명하다.Hereinafter, examples of the present invention will be described in detail, but the present invention is not limited by the following examples.
본 발명의 일 측면에 따르면, 부레옥잠 추출물을 유효성분으로 포함하는 화장료 조성물이 제공된다. 상기 화장료 조성물은 천연 유래의 추출물을 유효성분으로 포함하여 피부 개선 효과 및 생체 안전성이 우수할 뿐만 아니라 피부 자극이 최소화될 수 있다.According to one aspect of the invention, there is provided a cosmetic composition comprising the hyacinth extract as an active ingredient. The cosmetic composition may include an extract of natural origin as an active ingredient, as well as excellent skin improvement effect and biosafety, and may minimize skin irritation.
상기 화장료 조성물은 부레옥잠에 함유된 다양한 유효성분으로 인해 피부 주름 개선 및 미세먼지 흡착 효과뿐만 아니라, 항산화, 항염증, 피부 보습 효과가 우수하다.The cosmetic composition is excellent in antioxidant, anti-inflammatory, skin moisturizing effect, as well as skin wrinkle improvement and fine dust adsorption due to various active ingredients contained in water hyacinth.
상기 “부레옥잠(Eichhornia crassipes)”은 물옥잠과의 수생식물로써 열대, 아열대 지역에서 연중 수확이 가능한 식물이고, 국내에서는 수온이 20도 이상만 유지된다면 1년에 8회 이상 수확이 가능한 속성 식물이다. 수중 부영양화의 원인 원소인 질소와 인을 1,700 kg/ha, 300 kg/ha 수준으로 흡수 제거하는 능력을 가지고 있어 수중 정화 식물로도 이용된다. 상기 부레옥잠은 다양한 피부에 유익한 다양한 유효성분을 포함하므로 피부 개선을 위한 용도로 사용 가능하며 대기 중의 미세먼지를 흡착하는 효과가 우수하다.Eichhornia crassipes ) ”is an aquatic plant of the Aquaticaceae, which can be harvested year round in the tropical and subtropical regions, and is an attribute plant that can be harvested more than eight times a year if the water temperature is maintained at 20 degrees or higher. It has the ability to absorb and remove nitrogen and phosphorus, which are the causes of underwater eutrophication, at 1,700 kg / ha and 300 kg / ha. Since the water hyacinth contains a variety of effective ingredients beneficial to a variety of skin can be used for the purpose of improving the skin and has an excellent effect of adsorbing fine dust in the air.
상기 “추출물”은 용매와 추출 원료를 특정 조건 하에서 접촉시킴으로써 추출 원료에 함유된 유효성분이 전이된 용매를 지칭하는 것으로, 천연물로부터 원료에 함유된 성분을 분리해낸 물질이라면, 추출 방법이나 성분의 종류와 무관하게 모두 포함할 수 있다. 예컨대, 물이나 유기용매를 이용하여 천연물로부터 용매에 용해되는 성분을 추출한 것, 천연물의 특정 성분, 예컨대 오일과 같은 특정 성분만을 추출하여 얻어진 것 등을 모두 포함할 수 있다.The term "extract" refers to a solvent in which the active ingredient contained in the extract is transferred by contacting the solvent and the extract raw material under specific conditions. All may be included regardless. For example, extracting a component dissolved in a solvent from a natural product using water or an organic solvent, and may include both a specific component of the natural product, such as obtained by extracting only a specific component such as oil.
상기 혼합 추출물은 정제수, 탄소수 1 내지 4개의 저급 알코올, 아세톤, 에틸아세테이트, 부틸아세테이트, 및 1,3-부틸렌글라이콜로 이루어진 군으로부터 선택되는 하나 이상의 용매로 추출될 수 있고, 상기 알코올은 65 내지 75% 농도(v/v)의 에탄올일 수 있다.The mixed extract may be extracted with one or more solvents selected from the group consisting of purified water, lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, and 1,3-butylene glycol, wherein the alcohol is 65 to 75% concentration (v / v) of ethanol.
상기 원료에 포함된 유효성분은 용매의 극성에 따라 추출 비율이 상이해질 수 있으며, 상기 에탄올은 천연 원료의 생리 활성 물질 추출에 있어서 선택성이 뛰어나므로 상기 에탄올 추출에 의해 최적의 피부 개선 효과가 구현될 수 있다.The active ingredient contained in the raw material may be different in the extraction ratio according to the polarity of the solvent, the ethanol has excellent selectivity in the extraction of physiologically active substances of the natural raw material to achieve the optimal skin improvement effect by the ethanol extraction Can be.
물과 에탄올은 극성이 상이하여, 각 극성에 따라 추출되는 유효성분이 달라질 수 있으며 최적의 피부 개선 효과가 구현될 수 있도록 상기 에탄올의 농도를 적절히 제어할 수 있다. 이 때, 상기 에탄올의 농도가 75% 초과이면 적정한 수율이 구현되지 않을 수 있고, 65% 미만이면 피부 개선 효과를 나타내는 유효성분이 충분하게 추출되지 않을 수 있다.Water and ethanol are different in polarity, the active ingredient extracted according to each polarity can be different, and the concentration of the ethanol can be appropriately controlled so that the optimum skin improvement effect can be implemented. At this time, if the concentration of the ethanol is more than 75% may not be achieved a proper yield, if less than 65% may not be sufficiently extracted the effective ingredient showing the skin improvement effect.
상기 추출물은 추출 원료를 물로 수세한 후 건조 및 분쇄하여, 원료 중량의 8 내지 12배에 달하는 부피의 용매로 약 1시간 내지 24시간 동안 환류 순환 추출, 가압 추출, 초음파 추출 등 통상적인 방법으로 추출 및 여과하여 제조할 수 있다. 또한, 상기 추출물은 감압 증류 또는 동결 건조 등과 같은 추가적인 공정에 의해 분말 상태로 수득할 수 있다.The extract is washed with water, washed with water, dried and pulverized, and extracted with conventional methods such as reflux circulation extraction, pressure extraction, and ultrasonic extraction for about 1 to 24 hours with a solvent having a volume of 8 to 12 times the weight of the raw material. And may be prepared by filtration. In addition, the extract may be obtained in a powder state by an additional process such as distillation under reduced pressure or freeze drying.
상기 추출물은 통상적인 정제 과정을 거친 추출물도 포함할 수 있다. 예컨대, 상기 추출물은 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획물을 포함할 수 있다.The extract may also include an extract that has undergone conventional purification. For example, the extract may be subjected to various purification methods additionally performed, such as separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity, or affinity). It may comprise a fraction obtained through.
상기 화장료 조성물은 상기 부레옥잠 추출물에 발효 균주를 접종하여 제조된 발효 추출물을 포함할 수 있다. The cosmetic composition may include a fermentation extract prepared by inoculating a fermentation strain in the water hyacinth extract.
상기 “발효”는 특정 미생물이 효소를 이용해 유기물을 분해시키는 과정을 의미한다. 발효과정을 거친 원료는 유효성분의 특성 변화로 인해 발효 전보다 피부 개선 효과가 현저히 증대될 수 있다. 대사물질은 발효에 의해 피부에 유익한 각종 아미노산, 유기산, 항산화 물질을 함유하므로 피부대사를 촉진시키고 피부결에 탄력을 부여할 수 있다. 유효성분 입자는 발효에 의해 크기가 작아지고 중금속 등의 독성이 분해되어 피부트러블이나 알레르기 등 피부 부작용이 감소하고 흡수율이 증진될 수 있다.The term "fermentation" refers to a process in which a specific microorganism uses an enzyme to decompose organic matter. Raw materials that have undergone fermentation may have a significantly improved skin improvement effect than before fermentation due to changes in the properties of the active ingredient. Metabolites contain various amino acids, organic acids, and antioxidants that are beneficial to the skin by fermentation, thereby promoting skin metabolism and imparting elasticity to the skin texture. The active ingredient particles may be reduced in size by fermentation and decompose toxins such as heavy metals, thereby reducing side effects such as skin troubles and allergies and improving absorption.
상기 “발효 추출물”은 부레옥잠 추출물을 자연적으로 또는 회전감압농축기 및 동결건조기를 사용하여 건조시키고, 특정 용매에 일정 농도로 희석한 후 발효 균주를 접종하여 제조할 수 있다.The "fermented extract" may be prepared by inoculating fermented strains after the hyacinth extract is dried naturally or using a rotary pressure reducer and a lyophilizer, diluted to a certain concentration in a specific solvent.
상기 발효 균주는 락토바실러스 속(Lactobacillus sp .), 모나스커스 속(Monascus sp .), 비피도박테리아 속(Bifidobacterium sp .), 프레보텔라 속(Prevotella sp .), 푸조박테리아 속(Fusobacterium sp .), 및 유박테리아 속(Eubacterium sp .) 균주로 이루어진 군에서 하나 이상 선택될 수 있고, 바람직하게는 락토바실러스 속 균주일 수 있다.The fermentation strain is Lactobacillus genus (Lactobacillus sp.), Pseudomonas in coarse (Monascus sp.), Bacterial genus bifidobacteria (Bifidobacterium sp . ), Prevotella sp . , Fusobacterium sp . ), And Eubacterium sp . Strain, and may be selected from the group consisting of the strains of the genus Lactobacillus.
상기 락토바실러스 속 균주는 락토바실러스 김치쿠스(Lactobacillus kimchicus), 락토바실러스 펜토서스(Lactobacillus pentosus), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 카제이(Lactobacillus casei) 또는 락토바실러스 아시도필루스(Lactobacillus acidophilus)일 수 있으나, 바람직하게는 락토바실러스 김치쿠스(Lactobacillus kimchicus)일 수 있다.The strains of the genus Lactobacillus ( Lactobacillus kimchicus ), Lactobacillus pentosus ( Lactobacillus pentosus ), Lactobacillus brevis ( Lactobacillus brevis ), Lactobacillus plantarum ( Lactobacillus plantarum ), Lactobacillus casei (L) Or Lactobacillus acidophilus ( Lactobacillus acidophilus ), but may be preferably Lactobacillus kimchicus ( Lactobacillus kimchicus ).
상기 화장료 조성물은 유연화장수, 영양화장수, 수분크림, 영양크림, 마사지크림, 에센스, 앰플, 젤, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있다.The cosmetic composition is one or more selected from the group consisting of flexible cosmetics, nourishing cosmetics, moisture cream, nutrition cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and powder Can be formulated.
상기 화장료 조성물은 주름 개선용 또는 미세먼지 흡착용일 수 있고, 유연화장수, 수렴화장수, 영양화장수, 로션, 영양크림, 마사지크림, 에센스, 아이크림, 클렌징크림, 클렌징 폼, 클렌징워터, 팩, 스프레이, 및 파우더로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있다.The cosmetic composition may be for wrinkle improvement or fine dust adsorption, supple cosmetics, astringent cosmetics, nourishing cosmetics, lotions, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, And it may be formulated with one or more selected from the group consisting of a powder.
상기 화장료 조성물은 각각의 제형에 있어서 상기 유효성분 외 제형의 종류 또는 사용 목적 등에 따라 본 발명에 따른 목적을 저해하지 않는 범위 내에서 다른 성분들이 적절히 배합될 수 있다.The cosmetic composition may be appropriately blended with other ingredients within the range of not impairing the object according to the present invention in accordance with the type or purpose of use of the formulation other than the active ingredient in each formulation.
상기 화장료 조성물은 최종 제품의 품질이나 기능에 따라 지방 물질, 유기 용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉 쇄제, 킬레이트화제, 보존제, 차단제, 습윤화제, 필수 오일, 염료, 안료, 및 친수성 또는 친유성 활성제와 같은 화장료학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 추가적으로 포함할 수 있다.The cosmetic composition may be prepared according to the quality or function of the final product, such as fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, Commonly used in cosmetics or dermatology, such as ionic or nonionic emulsifiers, fillers, metal ion rod blockers, chelating agents, preservatives, blockers, wetting agents, essential oils, dyes, pigments, and hydrophilic or lipophilic active agents Supplement may be additionally included.
다만, 상기 보조제 및 그 혼합 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 영향을 미치지 않도록 적절히 선택하는 것이 바람직하다.However, the adjuvant and its mixing ratio are preferably selected appropriately so as not to affect the desirable properties of the cosmetic composition according to the present invention.
이하, 첨부된 도면을 참고하여 본 발명의 실시예에 관하여 상세히 서술하나, 하기 실시예에 의해 본 발명이 제한되지 아니함은 자명하다.Hereinafter, with reference to the accompanying drawings will be described in detail with respect to embodiments of the present invention, it is apparent that the present invention is not limited by the following examples.
실시예 1 : 부레옥잠 추출물Example 1 Water hyacinth extract
부레옥잠을 수세한 후 상온에서 건조시키고 분쇄하여 조분쇄물 100g을 수득하였다. 상기 각 분쇄물 100g을 10배 부피의 70% 농도(v/v) 에탄올에 침지하여 80℃의 온도에서 12시간 동안 환류 추출하였다. The water was washed with hyacinth, dried at room temperature and pulverized to obtain 100 g of coarse pulverized product. 100 g of each pulverized product was immersed in 10-fold volume of 70% concentration (v / v) ethanol and extracted under reflux for 12 hours at a temperature of 80 ° C.
상기 추출물을 250메쉬 및 0.5㎛ 여과지로 필터링하였으며 잔여 원료에 대해 동일한 방법으로 3회 반복 추출한 후 상온에서 냉각하였다. 상기 추출물은 20℃에서 감압 농축되었으며 동결 건조되어 고형으로 수득하였다.The extract was filtered with 250 mesh and 0.5 μm filter paper and extracted three times in the same manner for the remaining raw materials and then cooled at room temperature. The extract was concentrated under reduced pressure at 20 ° C. and lyophilized to give a solid.
실시예 2 : 부레옥잠 발효 추출물Example 2: Water hyacinth fermented extract
정제수로 실시예 1의 부레옥잠 추출물을 5중량%(v/v)로 희석한 후, 발효 균주인 비피도박테리움 비피덤(Bifidobacterium bifidum)을 접종하여 발효시켰다. 상기 발효 추출물을 500메쉬 및 0.2㎛ 여과지로 필터링하였으며 부레옥잠 발효 추출물을 수득하고 실시예 2의 시료로 하였다.After diluting the water hyacinth extract of Example 1 with purified water to 5% by weight (v / v), Bifidobacterium bifiderum ( Bifidobacterium) bifidum ) was inoculated and fermented. The fermented extract was filtered with 500 mesh and 0.2 μm filter paper to obtain a hyacinth fermented extract and used as a sample of Example 2.
실시예 3 : 부레옥잠 발효 추출물Example 3: Water hyacinth fermented extract
발효 균주로 락토바실러스 플란타룸(Lactobacillus plantarum)을 사용한 것을 제외하고는 실시예 2와 동일한 방법으로 실시예 3의 시료를 수득하였다.A sample of Example 3 was obtained in the same manner as in Example 2, except that Lactobacillus plantarum was used as the fermentation strain.
실시예 4 : 부레옥잠 발효 추출물Example 4: Water hyacinth fermented extract
발효 균주로 락토바실러스 김치쿠스(Lactobacillus kimchicus)를 사용한 것을 제외하고는 실시예 2와 동일한 방법으로 실시예 4의 시료를 수득하였다.A sample of Example 4 was obtained in the same manner as in Example 2 except for using Lactobacillus kimchicus as a fermentation strain.
실험예 1 : 피부 안전성 시험Experimental Example 1: Skin Safety Test
실시예 1 내지 4의 추출물의 피부 안전성을 검증하기 위해, 섬유아세포(HDF), 멜라닌형성세포(B16F10), 각질세포(HaCaT)에 대한 MTT assay 실험을 수행하였다.In order to verify skin safety of the extracts of Examples 1 to 4, MTT assay experiments were performed on fibroblasts (HDF), melanocytes (B16F10), and keratinocytes (HaCaT).
실시예 1 내지 4에서 수득된 시료를 정제수에 농도별로 현탁한 후, 세포 생존율을 측정하였다. After the samples obtained in Examples 1 to 4 were suspended in purified water by concentration, cell viability was measured.
실시예 1의 추출물은 0, 20, 40, 60, 80, 및 100 ug/mL의 농도로 현탁하였으며, 실시예 2 내지 4의 발효 추출물은 0.001, 0.005, 0.01, 0.05, 및 0.1 %의 농도(w/w)로 각각 현탁하였다.The extracts of Example 1 were suspended at concentrations of 0, 20, 40, 60, 80, and 100 ug / mL, and the fermentation extracts of Examples 2 to 4 were prepared at concentrations of 0.001, 0.005, 0.01, 0.05, and 0.1% ( w / w), respectively.
세포 독성은 MTT{3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide} 시약을 이용하여 세포 생존율을 측정하는 모스만(Mosmann)의 방법을 변형하여 실시하였다.Cytotoxicity was performed by modifying Mosmann's method of measuring cell viability using MTT {3- (4,5-dimethylthiazol-2-yl) -2-5-diphenyltetrazolium bromide} reagent.
섬유아세포(HDF), 멜라닌형성세포(B16F10), 및 각질세포(HaCaT)를 각각 96-웰 플레이트에 1×104 cells/well의 농도로 분주하여 37℃, 5 % CO2 에서 48 시간 동안 배양하였다.Fibroblasts (HDF), melanocytes (B16F10), and keratinocytes (HaCaT) were each dispensed in 96-well plates at a concentration of 1 × 10 4 cells / well and incubated at 37 ° C., 5% CO 2 for 48 hours. It was.
배양 배지를 제거하고 시료를 농도별로 처리한 배지에 48 시간 동안 배양한 후 배지를 제거하고 PBS(Phosphate buffered saline)로 반복 세척하였다. After removing the culture medium and incubating the sample for 48 hours in a concentration-treated medium, the medium was removed and washed repeatedly with PBS (Phosphate buffered saline).
MTT를 5 mg/mL 로 PBS에 녹여 50 L 첨가하고 37℃, 5 %의 CO2 에서 48 시간 동안 배양하였다. DMSO(Dimethyl sulfoxide)를 한 웰(well) 당 100 L 넣고, 10 분 동안 교반한 후 540 nm에서 흡광도를 측정하였다.MTT was dissolved in PBS at 5 mg / mL, 50 L was added, and incubated for 48 hours at 37 ° C. and 5% CO 2 . 100 L of DMSO (dimethyl sulfoxide) was added per well, stirred for 10 minutes, and the absorbance was measured at 540 nm.
측정 결과, 각 시료의 모든 농도에서 세포 독성은 확인되지 않았다. 상기 결과는 상기 추출물이 인체에 무해할 뿐만 아니라 인체 안전성이 우수함을 시사한다.As a result, no cytotoxicity was confirmed at all concentrations of each sample. The results suggest that the extract is not only harmless to the human body but also has excellent human safety.
실험예 2 : 항산화 활성 시험Experimental Example 2 Antioxidant Activity Test
활성산소 분해 효과Free radical decomposition effect
자유라디칼인 DPPH(1, 1-diphenyl -2-picryl hydrazyl)를 이용한 자유라디칼 소거활성 측정방법을 이용하여 활성산소 분해 효과를 확인하였다. The free radical scavenging activity was measured using the free radical DPPH (1, 1-diphenyl-2-picryl hydrazyl).
시험관에 4mL 메탄올을 넣고 상기 추출물의 농도를 달리하여 첨가하였다. 0.15mM DPPH 용액 1mL를 첨가하여 실온에서 30분간 반응시킨 후 520 nm에서 흡광도를 측정하였다. 4 mL methanol was added to the test tube, and the extract was added at different concentrations. 1 mL of 0.15 mM DPPH solution was added thereto to react at room temperature for 30 minutes, and the absorbance was measured at 520 nm.
기질과 DPPH가 없는 Initial(Ai)과 blank(Ab)를 측정하였으며, 양성대조군으로 α-tocopherol 및 BHT를 사용하였다. 결과는 하기 표 1에 나타내었다. Initial (Ai) and blank (Ab) without substrate and DPPH were measured, and α-tocopherol and BHT were used as positive controls. The results are shown in Table 1 below.
구분division 0 μg/mL0 μg / mL 20 μg/mL20 μg / mL 40 μg/mL40 μg / mL
α-tocopherolα-tocopherol 00 50.850.8 75.975.9
BHTBHT 00 42.442.4 66.766.7
실시예 1Example 1 00 39.339.3 61.461.4
실시예 2Example 2 00 42.642.6 66.166.1
실시예 3Example 3 00 45.245.2 69.769.7
실시예 4Example 4 00 47.747.7 73.273.2
[DPPH 소거율%][DPPH% Clearance]
상기 추출물은 당업계에 널리 알려진 α-tocopherol 및 BHT보다 자유라디칼 소거활성이 높은 것으로 평가되었다. 따라서, 상기 추출물에 의해 활성산소의 분해가 촉진될 수 있으며, 상기 결과는 항산화 활성에 의한 피부 노화 방지 및 피부 상태 개선 효과가 우수함을 시사한다.The extract was evaluated to have higher free radical scavenging activity than α-tocopherol and BHT, which are well known in the art. Therefore, the decomposition of free radicals may be promoted by the extract, and the results suggest that skin aging and skin condition improvement effect by the antioxidant activity is excellent.
세포 내의 활성산소종 측정시험(DCF-DA assay)Free radical species test in cells (DCF-DA assay)
실시예 1 내지 4의 추출물을 처리한 후 실리카(silica)로 자극한 세포 내에서 생성되는 활성산소종의 양을 음성대조군과 비교하여 활성산소종(reactive oxygen species; ROS) 제거능을 평가하였다(Cho et al., 1999; Kim et al., 2002). After treating the extracts of Examples 1 to 4, the amount of reactive oxygen species generated in the cells stimulated with silica was compared with the negative control group to evaluate the ability to remove reactive oxygen species (ROS) (Cho et al., 1999; Kim et al., 2002).
Raw 264.7 세포를 1×104 cells/well 농도로 96 웰 플레이트에 접종하여 배양하였다. 배지를 새로운 배지로 교환하고 상기 추출물을 처리한 후 24시간 동안 세포를 배양하였다. Raw 264.7 cells were incubated in 96 well plates at a concentration of 1 × 10 4 cells / well. The medium was exchanged with fresh medium and the cells were incubated for 24 hours after treatment of the extract.
각 웰에 WST-1용액(EZ-CYTOX, DOGEN, Korea)을 10.0 μL씩 넣고 1시간 동안 세포를 배양한 후 ELISA reader(Bio-Rad)로 measurement wavelength 450 nm, reference wavelength 655 nm에서 흡광도를 측정하였다. Add 10.0 μL of WST-1 solution (EZ-CYTOX, DOGEN, Korea) to each well, incubate the cells for 1 hour, and measure the absorbance at a measurement wavelength of 450 nm and reference wavelength of 655 nm with an ELISA reader (Bio-Rad). It was.
추출물은 최종농도 기준으로 최대 20μM이 되도록 dimethylsulfoxide(DMSO, Sigma-Aldrich, USA)로 희석하였으며 DMSO를 공시험액(음성대조군)으로 사용하였다. 신뢰도를 확보하고자 실험을 3회 반복하였다. The extract was diluted with dimethylsulfoxide (DMSO, Sigma-Aldrich, USA) to a maximum concentration of 20μM based on the final concentration, DMSO was used as a blank test (negative control). The experiment was repeated three times to secure the reliability.
상기 실험은 세포활성 측정시험인 WST-1 assay와 동일한 세포주 및 동일한 세포배양조건 하에서 실시되었다. 배양한 Raw 264.7 세포를 Phosphate Buffered Saline(PBS; sodium chloride 137 mM, phosphate buffer 10 mM, potassium chloride 2.7 mM, all from Biopure, Canada) 용액으로 1회 세척한 후 Raw 264.7 세포를 수확하였다. 15 mL PBS 용액으로 현탁하였으며 20 mM 2', 7'-Dichlorofluorescein diacetate 15 μL를 첨가하고 1시간 동안 배양하였다. The experiment was performed under the same cell line and the same cell culture conditions as the WST-1 assay, a cell activity measurement test. The cultured Raw 264.7 cells were washed once with a solution of Phosphate Buffered Saline (PBS; sodium chloride 137 mM, phosphate buffer 10 mM, potassium chloride 2.7 mM, all from Biopure, Canada) and then harvested Raw 264.7 cells. Suspended in 15 mL PBS solution, 15 μL of 20 mM 2 ', 7'-Dichlorofluorescein diacetate was added and incubated for 1 hour.
1200 rpm으로 2분간 원심분리한 후 PBS 용액으로 1회 세척하여 1×105 cells/mL로 희석한 후, 대조물질 및 추출물을 처리하고 10분간 배양하였다. 20 mg/mL의 실리카를 50 μL 처리하여 1시간 동안 배양하였다. 6000 rpm으로 5분간 원심분리하여 수득한 세포 펠릿(pellet)을 200 μL PBS 용액으로 분산시킨 후 96 웰 플레이트에 접종하였다.After centrifugation at 1200 rpm for 2 minutes, the solution was washed once with PBS solution, diluted to 1 × 10 5 cells / mL, treated with a control material and extract, and incubated for 10 minutes. 50 μL of 20 mg / mL silica was incubated for 1 hour. Cell pellets obtained by centrifugation at 6000 rpm for 5 minutes were dispersed in 200 μL PBS solution and seeded in 96 well plates.
fluorescence microplate reader를 이용하여 485 nm excitation / 535 nm emission에서 형광도를 측청하여 활성산소종 양을 평가하였다.The amount of reactive oxygen species was evaluated by measuring the fluorescence at 485 nm excitation / 535 nm emission using a fluorescence microplate reader.
검액 농도에 대한 활성산소종 측정시험에 처리한 추출물은 세포활성 측정을 통해 설정한 검액 농도로 사용하였다.The extract treated in the reactive oxygen species measurement test for the sample concentration was used as the sample concentration set by measuring the cell activity.
음성대조군으로는 시료물질 대신 DMSO를 사용하였으며, 양성대조군으로는 아스코르빈산(Sigma-Aldrich)을 DMSO에 100 mg/mL로 희석하여 100 μg/mL의 농도로 사용하였다. As a negative control, DMSO was used instead of the sample material. As a positive control, ascorbic acid (Sigma-Aldrich) was diluted to 100 mg / mL in DMSO and used at a concentration of 100 μg / mL.
상기 결과를 기반으로 동일 농도에 대한 활성산소종 측정시험을 수행하였으며, 처리한 추출물은 50 mg/L의 농도로 사용하였다. 신뢰도를 확보하고자 실험을 4회 반복하였다. 측정 결과는 하기 표 2과 같다. Based on the results, active oxygen species measurement test was performed for the same concentration, and the treated extract was used at a concentration of 50 mg / L. The experiment was repeated four times to secure the reliability. The measurement results are shown in Table 2 below.
구분division 0 μg/mL0 μg / mL 20 μg/mL20 μg / mL 40 μg/mL40 μg / mL
아스코르빈산Ascorbic acid 00 58.358.3 73.573.5
실시예 1Example 1 00 48.248.2 61.561.5
실시예 2Example 2 00 51.351.3 65.865.8
실시예 3Example 3 00 53.753.7 67.467.4
실시예 4Example 4 00 57.257.2 70.170.1
[ROS 생성억제율(% of control)] [% Of control]
상기 추출물은 당업계에 널리 알려진 아스코르빈산과 자유라디칼 소거활성이 동등한 수준으로 평가되었다. 즉, 상기 결과는 상기 실시예 1 내지 4의 활성산소종 제거능이 우수하며, 자유라디칼 소거활성으로 인한 항산화 효과가 뛰어남을 시사한다.The extract was evaluated to equal levels of ascorbic acid and free radical scavenging activity well known in the art. That is, the results suggest that the active oxygen species removal ability of Examples 1 to 4 is excellent, and the antioxidant effect due to free radical scavenging activity is excellent.
실험예 3 : 항염 활성 시험Experimental Example 3: Anti-inflammatory Activity Test
NF-kB 전사 억제 효과NF-kB transcription inhibitory effect
NF-kB reporter assay를 통해 NF-kB 전사 억제 효과를 측정하였다. LPS에 의해 유도되는 iNOS, COX-2, IFN-β 또는 TNF-α 등은 전사인자인 NF-kB 에 의해 발현된다. 상기 NF-kB 는 세포질에서는 IkB와 복합체 상태로 불활성화되어 있다가 I-kB-αkinase에 의해 I-kB-α가 인산화되면 결합되어 있던 복합체가 분해되어 NF-kB로 활성화되어 핵 내로 이동(translocation)한다. NF-kB의 표적유전자의 발현을 유도하여 염증작용을 일으킨다. NF-kB transcription inhibition effect was measured by NF-kB reporter assay. INOS, COX-2, IFN-β, TNF-α, etc. induced by LPS are expressed by the transcription factor NF-kB. The NF-kB is inactivated in complex with IkB in the cytoplasm. When I-kB-α is phosphorylated by I-kB-αkinase, the bound complex is decomposed and activated by NF-kB to move into the nucleus. )do. Induces expression of target gene of NF-kB and causes inflammatory action.
또한 다발성 경화증(multiple sclerosis)과 같은 염증질환에 작용하는 TRIF는 인터페론-β를 유발하는 수용체를 가지는 TIP-도메인으로 TLRs(toll-like-receptors)의 활성에 반응하는 수용체로서, 상기 TLRs는 침입 미생물의 특정 구성을 인식하여 항원에 대한 면역반응을 활성화한다. 상기 수용체는 잘 보존된 병원성 패턴을 인식해서 염증성 사이토카인의 방출을 자극하기 위해 신호를 활성화한다. IRF-3(인터페론자극유전인자3)은 인터페론α/β자극에 의해 유도되는 전사 활성화 인자로 대부분 인터페론 유도 유전자의 전사조절영역에 있는 인터페론자극반응순서(ISRE)에 결합하여 그 전사를 활성화한다.In addition, TRIF, which acts on inflammatory diseases such as multiple sclerosis, is a TIP-domain with an interferon-β-inducing receptor, which is a receptor that responds to the activity of TLRs (toll-like-receptors). It recognizes the specific composition of activating the immune response to the antigen. The receptor recognizes well-conserved pathogenic patterns and activates signals to stimulate the release of inflammatory cytokines. IRF-3 (interferon stimulatory gene 3) is a transcription activating factor induced by interferon α / β stimulation and binds to the interferon stimulation sequence (ISRE) in the transcriptional regulatory region of interferon-induced genes and activates its transcription.
제조자의 프로토콜(Jin et al., 2009)에 따라 12-웰 플레이트에 PEI 방법을 이용하여 β-갈락토시다제(β-galactosidase)와 같은 수용체 분자(MyD88 및 TRIF)의 존부에 따라 NF-kB-Luc 또는 TRIF 각각을 포함하는 플라스미드 1μg을 HEK293(1×106 cells/ml)세포에 주입(transfection)하였다. 24시간 동안 배양한 후 LPS(100 ng/ml) 및 상기 추출물을 처리하고, 24시간 후에 루시퍼라제 분석법(Luciferase assays)을 이용하여 NF-kB 의 활성 및 IRF-3 활성을 측정하였다. NF-kB depending on the presence of receptor molecules (MyD88 and TRIF), such as β-galactosidase, using the PEI method in 12-well plates according to the manufacturer's protocol (Jin et al., 2009). 1 μg of plasmid containing each of Luc or TRIF was transfected into HEK293 (1 × 10 6 cells / ml) cells. After culturing for 24 hours, LPS (100 ng / ml) and the extract were treated, and after 24 hours, luciferase assays were used to measure NF-kB activity and IRF-3 activity.
상기 루시퍼라제 분석법은 제조자의 프로토콜(Jung et al., 2009)에 보고된 루시퍼라제 분석 시스템(Promega Co., USA)을 이용하여 수행하였으며, 분석 결과는 하기 표 3과 같다.The luciferase assay was performed using a luciferase assay system (Promega Co., USA) reported in the manufacturer's protocol (Jung et al., 2009), and the analysis results are shown in Table 3 below.
구분division NF-kB 활성NF-kB activity IRF-3 활성IRF-3 activity
대조군(블랭크군)Control group (blank group) 1.001.00 1.001.00
실시예 1Example 1 0 μg/mL0 μg / mL 3.783.78 4.254.25
20 μg/mL20 μg / mL 2.122.12 2.262.26
40 μg/mL40 μg / mL 1.591.59 1.491.49
실시예 2Example 2 0 μg/mL0 μg / mL 3.723.72 4.234.23
20 μg/mL20 μg / mL 2.092.09 2.182.18
40 μg/mL40 μg / mL 1.521.52 1.441.44
실시예 3Example 3 0 μg/mL0 μg / mL 3.653.65 4.164.16
20 μg/mL20 μg / mL 2.052.05 2.162.16
40 μg/mL40 μg / mL 1.521.52 1.421.42
실시예 4Example 4 0 μg/mL0 μg / mL 3.633.63 4.124.12
20 μg/mL20 μg / mL 2.022.02 2.122.12
40 μg/mL40 μg / mL 1.371.37 1.351.35
[Fold, Luciferase activity] [Fold, Luciferase activity]
표 3을 참조하면, 상기 추출물을 처리하는 경우 NF-kB의 활성 및 IRF-3의 활성이 현저히 감소하였다. 상기 결과는 상기 추출물이 NF-kB의 전사를 효과적으로 억제하므로 이를 통해 염증을 저해 또는 완화시킬 수 있으며 염증 질환의 예방 및 개선 효과가 있음을 시사한다.Referring to Table 3, the treatment of the extract significantly reduced the activity of NF-kB and IRF-3. The results suggest that the extract effectively inhibits the transcription of NF-kB, thereby inhibiting or alleviating inflammation and preventing and improving inflammatory diseases.
염증 관련 단백질 mRNA 정량 분석Inflammation-related Protein mRNA Quantitation
TNF-α, iNOS, 및 COX-2의 발현량을 분석하여 상기 추출물의 항염활성을 평가하였다.The anti-inflammatory activity of the extract was evaluated by analyzing the expression levels of TNF-α, iNOS, and COX-2.
LPS를 처리한 RAW264.7 세포로부터 RNA를 준비하였다. 상기 방법은 Lee et al., 2008에 기재된 바에 따라 Trizol Reagent(Gibco BRL)을 이용하여 준비하였다. 모든 RNA는 -70℃에서 보관한 후 사용하였다. Semi-quantitative RT 반응은 MuLV reverse transcriptase를 이용하여 수행하였다. RNA was prepared from LPS treated RAW264.7 cells. The method was prepared using Trizol Reagent (Gibco BRL) as described by Lee et al., 2008. All RNA was used after storage at -70 ℃. Semi-quantitative RT reaction was performed using MuLV reverse transcriptase.
모든 RNA(1㎍)는 oligo-dT15로 70℃에서 5분 동안 배양되었고, 5×first strand buffer, 10 mM dNTPs 및 0.1 M DTT와 혼합하였다. 반응 혼합물은 37℃에서 5 분 동안 더 배양하고, MuLV reverse transcriptase(2 U)를 첨가한 후에 60 분간 배양하였다. 70℃에서 10분간 배양하여 반응을 종결시켰다. RNase H를 첨가하여 모든 RNA를 제거하고, PCR반응을 수행하였다(conditions: 2 μL cDNA, 4 μM 5' and 3' 프라이머, 10×buffer(10 mM Tris-HCl, pH 8.3; 50 mM KCl and 0.1% Triton X-100), 250 μM dNTPs, MgCl2 25 mM 및 Taq DNA 중합효소 1unit(Promega, USA). PCR 반응은 94℃에서 30 초간 변성시키고, 55 내지 60℃에서 30 초간 어닐링 한 후에, 72℃에서 42초간 중합하고, 72℃에서 5분간 최종적으로 중합하였다.All RNA (1 μg) was incubated with oligo-dT15 at 70 ° C. for 5 minutes and mixed with 5 × first strand buffer, 10 mM dNTPs and 0.1 M DTT. The reaction mixture was further incubated at 37 ° C. for 5 minutes and incubated for 60 minutes after the addition of MuLV reverse transcriptase (2 U). The reaction was terminated by incubating at 70 ° C. for 10 minutes. RNase H was added to remove all RNA and PCR reactions were performed (conditions: 2 μL cDNA, 4 μM 5 ′ and 3 ′ primers, 10 × buffer (10 mM Tris-HCl, pH 8.3; 50 mM KCl and 0.1). % Triton X-100), 250 μΜ dNTPs, 25 mM MgCl 2 and 1 unit of Taq DNA polymerase (Promega, USA) The PCR reaction was denatured at 94 ° C. for 30 seconds and after annealing at 55 to 60 ° C. for 30 seconds, 72 It superposed | polymerized at 42 degreeC for 42 second, and finally superposed | polymerized at 72 degreeC for 5 minutes.
TNF-α, iNOS, 및 COX-2의 프라이머는 하기 표 4와 같다.Primers of TNF-α, iNOS, and COX-2 are shown in Table 4 below.
구분division 정방향 프라이머Forward primer 역방향 프라이머Reverse primer
iNOSiNOS 5'-FGGAGCCTTTAGACCTCAACAGA-3'5'-FGGAGCCTTTAGACCTCAACAGA-3 ' 5'-RTGAACGAGGAGGGTGGTG-3'5'-RTGAACGAGGAGGGTGGTG-3 '
TNF-αTNF-α 5'-FTGCCTATGTCTCAGCCTCTTC-3'5'-FTGCCTATGTCTCAGCCTCTTC-3 ' 5'-RGAGGCCATTTGGGAACTTCT-3'5'-RGAGGCCATTTGGGAACTTCT-3 '
COX-2COX-2 5'-FCACTACATCCTGACCCACTT-3'5'-FCACTACATCCTGACCCACTT-3 ' 5'-RATGCTCCTGCTTGAGTATGT-3'5'-RATGCTCCTGCTTGAGTATGT-3 '
상기 추출물 처리에 따른 mRNA 발현량 측정 결과는 하기 표 5와 같다. RAW264.7 세포의 mRNA를 분석한 결과 LPS의 첨가에 의해, TNF-α, iNOS, 및 COX-2의 발현이 증가하였다. 반면, 상기 LPS에 의해 유도된 TNF-α, iNOS, 및 COX-2의 발현은 상기 추출물을 처리했을 때 발현량이 농도 의존적으로 감소하였다. MRNA expression level measurement results according to the extract treatment is shown in Table 5. MRNA analysis of RAW264.7 cells resulted in increased expression of TNF-α, iNOS, and COX-2 by the addition of LPS. On the other hand, the expression of TNF-α, iNOS, and COX-2 induced by LPS decreased in a concentration-dependent manner when the extract was treated.
구분division iNOS 발현량iNOS expression level TNF-α 발현량TNF-α expression level COX-2 발현량COX-2 expression level
대조군(블랭크군)Control group (blank group) 1.001.00 1.001.00 1.001.00
실시예 1Example 1 0%(w/w)0% (w / w) 3.453.45 3.103.10 3.203.20
0.01%(w/w)0.01% (w / w) 2.202.20 1.751.75 2.102.10
0.1%(w/w)0.1% (w / w) 1.601.60 1.351.35 1.801.80
실시예 2Example 2 0%(w/w)0% (w / w) 3.353.35 3.063.06 3.153.15
0.01%(w/w)0.01% (w / w) 2.152.15 1.691.69 2.052.05
0.1%(w/w)0.1% (w / w) 1.521.52 1.301.30 1.671.67
실시예 3Example 3 0%(w/w)0% (w / w) 3.313.31 3.033.03 3.103.10
0.01%(w/w)0.01% (w / w) 2.052.05 1.641.64 2.012.01
0.1%(w/w)0.1% (w / w) 1.451.45 1.231.23 1.561.56
실시예 4Example 4 0%(w/w)0% (w / w) 3.253.25 2.952.95 3.013.01
0.01%(w/w)0.01% (w / w) 1.961.96 1.541.54 1.951.95
0.1%(w/w)0.1% (w / w) 1.361.36 1.191.19 1.341.34
[Fold, GAPDH normalized] [Fold, GAPDH normalized]
실험예 4 : 피부 보습 효과 평가Experimental Example 4 Evaluation of Skin Moisturizing Effect
실시예 1 내지 4에서 수득한 시료 분말을 정제수에 현탁하여 농도별로 희석하고 피부 보습 효과를 평가하였다.The sample powders obtained in Examples 1 to 4 were suspended in purified water, diluted by concentration, and the skin moisturizing effect was evaluated.
인간각질형성세포주(Keratinocytes)에서 피부보습에 관여하는 HAS2 유전자 및 AQP3 유전자의 발현정도를 mRNA 수준에서 측정하였다.The expression level of the HAS2 gene and AQP3 gene involved in skin moisturization in human keratinocytes (Keratinocytes) was measured at the mRNA level.
인간 각질세포(HaCaT)를 Dulbecco's Modified Eagle's Medium(DMEM), 10% Fatal bovine serum(FBS), 1% Antibiotic-Antimycotic과 함께 100 mm/60.1 cm culture dish에서 37℃, 5% CO2의 조건으로 배양하였다. Human keratinocytes (HaCaT) were incubated at 37 ° C and 5% CO 2 in a 100 mm / 60.1 cm culture dish with Dulbecco's Modified Eagle's Medium (DMEM), 10% Fatal bovine serum (FBS) and 1% Antibiotic-Antimycotic. It was.
각질세포를 1x106세포/mL농도로 96 웰 플레이트에 분주하여, 24시간 동안 배양하였다. DMEM free 배지로 교환 후 농도별로 희석한 실시예 1 내지 4의 추출물을 처리하고 24시간 동안 배양하였다.Keratinocytes were dispensed into 96 well plates at a concentration of 1 × 10 6 cells / mL and incubated for 24 hours. After exchange with DMEM free medium was treated extracts of Examples 1 to 4 diluted by concentration and incubated for 24 hours.
세포를 회수하여 냉각된 인산완충용약(PBS)로 세척하고 트리졸 시약[TRIzol™reagent, 라이프 테크놀로지스, 인크(Life Technologies, Inc.)] 1ml를 첨가하고 총 RNA를 추출하였다. Cells were recovered, washed with cold phosphate buffer (PBS), 1 ml of Trizol reagent [TRIzol ™ reagent, Life Technologies, Inc.] was added and total RNA extracted.
유전자 발현 변화는 중합효소 연쇄 반응(PCR)에서 증폭되는 DNA 산물에 형광물질을 결합하고 형광물질을 지속적으로 검출하는 qRT-PCR(quantitative real time PCR)로 측정하였다.Gene expression changes were measured by qRT-PCR (quantitative real time PCR), which binds the fluorescent material to the DNA product amplified in the polymerase chain reaction (PCR) and continuously detects the fluorescent material.
HAS2 및 AQP3 유전자 발현의 변화를 정량하고자 SYBR green Ⅰ(Invitrogen)을 통해 PCR 산물이 발산하는 형광값을 측정하였다. PCR tube에 0.2μM 프라이머, 50 mM KCl, 20 mM Tris/HCl pH 8.4, 0.8 mM dNTP, 0.5U Extaq DNA polymerase, 3 mM MgCl2, 1×SYBR green을 혼합하여 반응액을 제조하였다.In order to quantify changes in HAS2 and AQP3 gene expression, fluorescence values emitted by PCR products were measured through SYBR green I (Invitrogen). A reaction solution was prepared by mixing 0.2 μM primer, 50 mM KCl, 20 mM Tris / HCl pH 8.4, 0.8 mM dNTP, 0.5U Extaq DNA polymerase, 3 mM MgCl 2 , and 1 × SYBR green.
Linegene K(BioER, China)를 이용하여 94℃에서 3분 동안 예비적 변성(primary denaturation) 시킨 후 변성(denaturation), 어닐링(annealing), 중합(polymerization)을 94℃에서 30초, 58℃에서 30초, 72℃에서 30초로 총 40 cycle을 수행하였고, 매 cycle 이 종료된 후 형광강도를 측정하였다.Preliminary denaturation at 94 ° C for 3 minutes with Linegene K (BioER, China) followed by denaturation, annealing and polymerization at 94 ° C for 30 seconds, 58 ° C at 30 ° C A total of 40 cycles were performed for 30 seconds at 72 ° C., and the fluorescence intensity was measured after each cycle.
PCR 결과는 각 결과별 melting curve로 검증하였다. 각 유전자의 threshold cycle(Ct)값을 β-actin의 Ct값으로 표준화한 후, Ct값의 변화량을 비교하여 분석하였다.PCR results were verified by melting curve for each result. The threshold cycle (Ct) of each gene was normalized to the Ct of β-actin, and then analyzed by comparing the change in Ct.
Ct값은 PCR 산물에 의해 발생하는 형광의 양(증폭된 PCR 산물의 수)이 기본 값 이상의 일정한 기준 값에 도달했을 때의 cycle 수로서 Ct값을 통하여 유전자 발현량을 확인할 수 있다. 실험에 사용한 프라이머 서열은 하기 표 6과 같다.The Ct value is the number of cycles when the amount of fluorescence generated by the PCR product (the number of amplified PCR products) reaches a predetermined reference value above the basic value. Primer sequences used in the experiment are shown in Table 6 below.
GeneGene 정방향 프라이머Forward primer 역방향 프라이머Reverse primer
HAS-2HAS-2 5'-TTTCTTTATGTGACTCATCTGTCTCACCGG-3'5'-TTTCTTTATGTGACTCATCTGTCTCACCGG-3 ' 5'-ATTGTTGGCTACCAGTTTATCCAAAGGG-3'5'-ATTGTTGGCTACCAGTTTATCCAAAGGG-3 '
AQP3AQP3 5′- ACCCTCATCCTGGTGATGTTTG-3′5′- ACCCTCATCCTGGTGATGTTTG-3 ′ 5′- TCTGCTCCTTGTGCTTCACAT-3′5′- TCTGCTCCTTGTGCTTCACAT-3 ′
HAS2 및 AQP3 mRNA 발현량 측정 결과는 하기 표 7과 같으며, mRNA 발현량은 상기 추출물의 처리에 따라 농도 의존적으로 증가하였다. HAS2 및 AQP3 발현 촉진능이 높을수록 피부 보습 효과가 우수한 것으로 평가할 수 있다. HAS2 and AQP3 mRNA expression level measurement results are shown in Table 7 below, mRNA expression level was increased concentration-dependently according to the treatment of the extract. The higher the HAS2 and AQP3 expression promoting ability can be evaluated as an excellent skin moisturizing effect.
상기 결과는 상기 추출물이 아쿠아포린 단백질의 발현 및 히알루론산의 합성을 촉진시킴으로써 피부 보습을 증진시킬 수 있음을 시사한다.The results suggest that the extract can enhance skin moisturization by promoting the expression of aquaporin protein and the synthesis of hyaluronic acid.
구분division HAS2 발현량HAS2 expression level AQP3 발현량AQP3 expression level
실시예 1Example 1 0 μg/mL0 μg / mL 1.001.00 1.001.00
50 μg/mL50 μg / mL 1.231.23 1.071.07
100 μg/mL100 μg / mL 1.861.86 1.241.24
실시예 2Example 2 0 μg/mL0 μg / mL 1.001.00 1.001.00
50 μg/mL50 μg / mL 1.471.47 1.161.16
100 μg/mL100 μg / mL 2.212.21 1.371.37
실시예 3Example 3 0 μg/mL0 μg / mL 1.001.00 1.001.00
50 μg/mL50 μg / mL 1.611.61 1.261.26
100 μg/mL100 μg / mL 2.432.43 1.481.48
실시예 4Example 4 0 μg/mL0 μg / mL 1.001.00 1.001.00
50 μg/mL50 μg / mL 1.761.76 1.351.35
100 μg/mL100 μg / mL 2.862.86 1.541.54
[Fold of control] [Fold of control]
실험예 5 : 콜라겐 생합성 유도 시험Experimental Example 5: Collagen Biosynthesis Induction Test
섬유아세포의 생장에 따른 콜라겐의 합성 여부를 관찰하였다.The synthesis of collagen according to the growth of fibroblasts was observed.
1.0×104세포/mL농도로 인간진피섬유아세포를 96 웰 플레이트에 100μL씩 분주하고, 37℃, 5% C02, 가습 조건하에서 3일간 배양하였다. Medium 106S(쿠라시키보세키 가부시키가이샤 제조)에 LSGS(Low Serum Growth Supplement, 쿠라시키보세키 가부시키가이샤 제조)를 10 중량%로 함유한 배지를 웰 당 100μL씩 사용하였다.Human dermal fibroblasts were dispensed in 96 well plates at a concentration of 1.0 × 10 4 cells / mL, and cultured for 3 days at 37 ° C., 5% CO 2 , and humidified conditions. A medium containing 10 wt% of LSGS (Low Serum Growth Supplement, manufactured by Kurashiki Boseki Co., Ltd.) in Medium 106S (manufactured by Kurashiki Boseki Co., Ltd.) was used at 100 µL per well.
배지를 DMEM(Dulbecco's Modified Eagle's Medium, Sigma社 제조)으로 교환하고, 실시예 1 내지 4추출물을 50 mg/L 농도로 처리한 후 배양하였다. 상기 추출물을 처리하지 않고 정제수를 첨가한 것을 대조군으로 사용하였다. The medium was exchanged with DMEM (Dulbecco's Modified Eagle's Medium, manufactured by Sigma), and incubated after treating the extracts 1 to 4 at a concentration of 50 mg / L. Purified water was added without treating the extract as a control.
상기 세포를 7일간 배양한 후 배양액을 채취하고, 효소 결합 면역 측정법(Procollagen type I c-peptide EIA Kit; 타카라바이오 가부시키가이샤 제조)을 통해 배양액 중 분비된 타입 I 콜라겐 농도를 정량하였다.After culturing the cells for 7 days, the culture medium was collected, and the concentration of type I collagen secreted in the culture medium was quantified by an enzyme-linked immunoassay (Procollagen type I c-peptide EIA Kit; manufactured by Takara Bio Co., Ltd.).
대조군의 타입 I 콜라겐 양을 기준(100%)으로 하여 각 시험 샘플 배양액 중의 콜라겐 양을 산출하였으며, 측정 결과는 하기 표 8과 같다.The amount of collagen in each test sample culture was calculated based on the type I collagen amount of the control group (100%), and the measurement results are shown in Table 8 below.
구분division 콜라겐 생산량(%)Collagen Production (%)
실시예 1Example 1 171.3171.3
실시예 2Example 2 182.8182.8
실시예 3Example 3 191.5191.5
실시예 4Example 4 198.3198.3
대조군Control 101.2101.2
실험예 6 : COL1A1 및 MMP1의 발현 측정 시험Experimental Example 6: Expression Measurement Test of COL1A1 and MMP1
실시예 1 내지 4에서 수득한 시료 분말을 정제수에 현탁하여 농도별로 희석하고 주름 개선 효과를 평가하였다.The sample powders obtained in Examples 1 to 4 were suspended in purified water, diluted by concentration, and the effect of improving wrinkles was evaluated.
인간진피섬유아세포가 발현하는 대표적인 콜라겐(collagen) 중 하나인 COL1A1, 탄력단백질(elastin) 중 하나인 ELN 및 콜라겐 분해효소인 MMP1의 발현 변화를 측정하였다.Changes in the expression of COL1A1, one of the representative collagens expressed by human dermal fibroblasts, ELN, one of the elastins, and MMP1, a collagen degrading enzyme, were measured.
콜라겐의 발현 변화 정도를 확인하고자 농도별로 희석한 실시예 1 내지 4의 추출물을 인간 진피섬유아세포에 처리하고 24시간 동안 배양하였다.The extracts of Examples 1 to 4 diluted by concentration were treated to human dermal fibroblasts and cultured for 24 hours to determine the degree of collagen expression change.
유전자 발현 변화는 중합효소 연쇄 반응(PCR)에서 증폭되는 DNA 산물에 형광물질을 결합하고 형광물질을 지속적으로 검출하는 qRT-PCR(quantitative real time PCR)로 측정하였다.Gene expression changes were measured by qRT-PCR (quantitative real time PCR), which binds the fluorescent material to the DNA product amplified in the polymerase chain reaction (PCR) and continuously detects the fluorescent material.
COL1A1 및 MMP1 유전자 발현의 변화를 정량하고자 SYBR green Ⅰ(Invitrogen)을 통해 PCR 산물이 발산하는 형광값을 측정하였다. PCR tube에 0.2μM 프라이머, 50 mM KCl, 20 mM Tris/HCl pH 8.4, 0.8 mM dNTP, 0.5U Extaq DNA polymerase, 3 mM MgCl2, 1×SYBR green을 혼합하여 반응액을 제조하였다.In order to quantify changes in COL1A1 and MMP1 gene expression, the fluorescence values emitted by PCR products were measured through SYBR green I (Invitrogen). A reaction solution was prepared by mixing 0.2 μM primer, 50 mM KCl, 20 mM Tris / HCl pH 8.4, 0.8 mM dNTP, 0.5U Extaq DNA polymerase, 3 mM MgCl 2 , and 1 × SYBR green.
Linegene K(BioER, China)를 이용하여 94℃에서 3분 동안 예비적 변성(primary denaturation) 시킨 후 변성(denaturation), 어닐링(annealing), 중합(polymerization)을 94℃에서 30초, 58℃에서 30초, 72℃에서 30초로 총 40 cycle을 수행하였고, 매 cycle 이 종료된 후 형광강도를 측정하였다.Preliminary denaturation at 94 ° C for 3 minutes with Linegene K (BioER, China) followed by denaturation, annealing and polymerization at 94 ° C for 30 seconds, 58 ° C at 30 ° C A total of 40 cycles were performed for 30 seconds at 72 ° C., and the fluorescence intensity was measured after each cycle.
PCR 결과는 각 결과별 melting curve로 검증하였다. 각 유전자의 threshold cycle(Ct)값을 β-actin의 Ct값으로 표준화한 후, Ct값의 변화량을 비교하여 분석하였다.PCR results were verified by melting curve for each result. The threshold cycle (Ct) of each gene was normalized to the Ct of β-actin, and then analyzed by comparing the change in Ct.
Ct값은 PCR 산물에 의해 발생하는 형광의 양(증폭된 PCR 산물의 수)이 기본 값 이상의 일정한 기준 값에 도달했을 때의 cycle 수로서 Ct값을 통하여 유전자 발현량을 확인할 수 있다. 실험에 사용한 프라이머 서열은 하기 표 9와 같다.The Ct value is the number of cycles when the amount of fluorescence generated by the PCR product (the number of amplified PCR products) reaches a predetermined reference value above the basic value. Primer sequences used in the experiment are shown in Table 9 below.
GeneGene 정방향 프라이머Forward primer 역방향 프라이머Reverse primer
β-actinβ-actin 5-GGATTCCTATGTGGGCGACGA-35-GGATTCCTATGTGGGCGACGA-3 5-CGCTCGGTGAGGATCTTCATG-35-CGCTCGGTGAGGATCTTCATG-3
COL1A1COL1A1 5-AGGGCCAAGACGAAGACATC-35-AGGGCCAAGACGAAGACATC-3 5-AGATCACGTCATCGCACAACA-35-AGATCACGTCATCGCACAACA-3
MMP1MMP1 5-TCTGACGTTGATCCCAGAGAGCAG-35-TCTGACGTTGATCCCAGAGAGCAG-3 5-CAGGGTGACACCAGTGACTGCAC-35-CAGGGTGACACCAGTGACTGCAC-3
상기 추출물의 처리에 따른 발현량 측정 결과는 하기 표 10과 같다. COL1A1 mRNA의 발현량은 농도 의존적으로 증가한 반면, MMP1 mRNA 발현량은 농도 의존적으로 감소하였다. Expression measurement results according to the treatment of the extract is shown in Table 10 below. The expression level of COL1A1 mRNA increased in a concentration dependent manner, whereas the expression level of MMP1 mRNA decreased in a concentration dependent manner.
MMP-1 발현 저해능이 높을수록 피부 주름 개선 및 항노화 효과가 우수한 것으로 평가할 수 있으며, 상기 결과는 상기 추출물이 콜라겐의 생성을 촉진하고 이를 통해 피부 탄력 및 주름을 개선할 수 있는 바 피부 미용의 용도로서 활용 가능함을 시사한다. The higher the MMP-1 expression inhibitory ability can be evaluated that the skin wrinkle improvement and anti-aging effect is excellent, the result is that the extract can promote the production of collagen and thereby improve the skin elasticity and wrinkles bar use of skin care It can be used as
구분division COL1A1 발현량COL1A1 expression level MMP1 발현량MMP1 expression level
실시예 1Example 1 0%(w/w)0% (w / w) 1.001.00 1.001.00
0.01%(w/w)0.01% (w / w) 1.821.82 0.790.79
0.1%(w/w)0.1% (w / w) 2.622.62 0.450.45
실시예 2Example 2 0%(w/w)0% (w / w) 1.001.00 1.001.00
0.01%(w/w)0.01% (w / w) 1.891.89 0.770.77
0.1%(w/w)0.1% (w / w) 2.952.95 0.420.42
실시예 3Example 3 0%(w/w)0% (w / w) 1.001.00 1.001.00
0.01%(w/w)0.01% (w / w) 2.072.07 0.790.79
0.1%(w/w)0.1% (w / w) 3.093.09 0.400.40
실시예 4Example 4 0%(w/w)0% (w / w) 1.001.00 1.001.00
0.01%(w/w)0.01% (w / w) 1.951.95 0.720.72
0.1%(w/w)0.1% (w / w) 3.163.16 0.370.37
[Fold, β-actin normalized] [Fold, β-actin normalized]
실험예 7 : 주름 개선 평가Experimental Example 7: Wrinkle improvement evaluation
40 내지 60세의 여성 50명을 대상으로 실시예 1 내지 4의 추출물을 제형화한 로션을 매일 아침 저녁 2회씩 안면에 1개월간 적용하고 주름 개선 정도를 평가하였다.The lotion formulated with extracts of Examples 1 to 4 was applied to 50 women aged 40 to 60 years every morning and evening twice a month for 1 month to evaluate the degree of wrinkle improvement.
주름 평가법(Replica analysis)을 통해 각 피검자의 전체 주름 수, 주름 길이, 주름 면적을 측정하여 수치화하였으며 영상분석을 통해 주름 개선 정도를 평가하였다. 평가 결과는 하기 표 11과 같다. Through wrinkle analysis, the total number of wrinkles, the length of wrinkles, and the area of wrinkles were measured and quantified, and the degree of wrinkle improvement was evaluated through image analysis. The evaluation results are shown in Table 11 below.
구분division 총 주름 수 감소율(%)% Reduction in total wrinkles 주름 면적 감소율(%)Wrinkle Area Reduction (%) 주름 길이 감소율(%)Wrinkle Length Reduction (%)
실시예 1Example 1 0주Week 0 0.00.0 0.00.0 0.00.0
4주4 Weeks 20.020.0 8.28.2 8.58.5
8주8 Weeks 22.722.7 11.411.4 15.815.8
12주12 Weeks 24.924.9 19.819.8 23.823.8
실시예 2Example 2 0주Week 0 0.00.0 0.00.0 0.00.0
4주4 Weeks 22.522.5 9.59.5 10.310.3
8주8 Weeks 23.823.8 14.214.2 18.918.9
12주12 Weeks 26.226.2 22.622.6 25.825.8
실시예 3Example 3 0주Week 0 0.00.0 0.00.0 0.00.0
4주4 Weeks 23.823.8 10.210.2 12.812.8
8주8 Weeks 25.725.7 15.715.7 21.321.3
12주12 Weeks 28.528.5 24.624.6 27.527.5
실시예 4Example 4 0주Week 0 0.00.0 0.00.0 0.00.0
4주4 Weeks 25.925.9 12.412.4 13.613.6
8주8 Weeks 28.828.8 17.817.8 25.325.3
12주12 Weeks 31.231.2 29.529.5 32.432.4
표 11을 참조하면, 실시예 1 내지 4의 추출물을 제형화한 크림은 피부주름 파라미터인 전체 주름 수, 주름 면적, 주름 길이를 현저히 감소시켰으며, 상기 결과는 상기 추출물이 피부 주름 개선 및 피부 미용의 용도로서의 활용될 수 있음을 시사한다.Referring to Table 11, the cream formulated with the extracts of Examples 1 to 4 significantly reduced the total number of wrinkles, wrinkle area, wrinkle length, skin wrinkle parameters, the result is that the extract improves skin wrinkles and skin beauty It can be used as a purpose.
실험예 8 : 피부결 개선 효과 평가Experimental Example 8: Evaluation of skin texture improvement effect
실시예 1 내지 4의 추출물을 제형화한 크림의 피부결 개선 효과를 검증하였다.The skin texture improvement effect of the cream formulated extract of Examples 1 to 4 was verified.
대조군으로 공지의 추출물 중 보습 기능이 있다고 알려진 알로에베라 추출물을 제형화한 크림을 사용하였다.As a control, a cream formulated with aloe vera extract, which is known to have a moisturizing function, was used.
20 내지 40세의 여성 중 선정된 40명에 대하여 PRIMOS 라이트(field of view 45, flexible 3D measuring, GFMesstechnik GmbH)를 이용하여 시험 대상자의 사용 전 피부를 측정하고, 상기 크림을 사용한 후 피부를 재측정하였다.Forty women among 20 to 40 year olds were measured using PRIMOS light (field of view 45, flexible 3D measuring, GFMesstechnik GmbH) to measure skin prior to use of the subject and re-measure skin after using the cream. It was.
측정값은 Ra의 최대값과 최소값을 제외한 3회의 평균값으로 나타내었다. 측정값이 높을수록 피부 주름이 많은 상태를 의미하며, 평과 결과를 하기 표 12와 같다.The measured value was expressed as the average of three times except the maximum value and minimum value of Ra. The higher the measured value means a lot of skin wrinkles, the results are shown in Table 12.
[Ra, (Arbitrary unit)][Ra, (Arbitrary unit)]
구분division 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 대조군Control
사용 전Before use 15.7015.70 15.7315.73 15.6015.60 15.6815.68 15.7015.70
2주 후2 weeks later 14.2614.26 13.9513.95 13.5513.55 12.9712.97 14.5414.54
4주 후4 weeks later 12.2512.25 11.9611.96 11.7611.76 10.9510.95 13.9113.91
표 12를 참고하면, 실시예 1 내지 4의 추출물을 제형화한 크림을 사용한 실험군은 사용 후 측정값이 현저하게 감소하여 피부결 개선 효과가 현저히 우수한 것으로 평가되었다.Referring to Table 12, the experimental group using the cream formulated with the extract of Examples 1 to 4 was evaluated that the measured value after use is significantly reduced and the skin texture improvement effect is remarkably excellent.
특히, 부레옥잠 락토바실러스 김치쿠스 발효 추출물이 포함된 크림(실시예 4)의 피부결 개선 효과가 가장 우수한 것으로 확인되었고, 부레옥잠 추출물이 함유되지 않은 대조군의 크림을 사용한 경우, 피부결 개선 효과가 현저히 미흡하였다.In particular, it was confirmed that the cream containing the hyacinth lactobacillus kimchicus fermented extract (Example 4) has the most excellent skin texture improvement effect, when the cream of the control group does not contain the hyacinth extract, the skin texture improvement effect is significantly insufficient. It was.
실험예 9 : 다환방향족탄화수소 제거 효과 시험Experimental Example 9 Polycyclic Aromatic Hydrocarbon Removal Effect Test
미세먼지 중 다량 함유된 유해대기물질인 다환방향족탄화수소(polycyclic aromatic hydrocarbons: PAH)의 흡착 효과를 시험하였다.The adsorption effect of polycyclic aromatic hydrocarbons (PAH), which is a large amount of harmful air in fine dust, was tested.
털을 제거한 돼지 외피(1cm x 1cm) 시편을 준비한 후, PBS로 10분간 세척하였다.After removing the fur of the pig skin (1cm x 1cm) specimens were prepared and washed with PBS for 10 minutes.
세척 후 나프탈렌(Naphtalene), 아세나프틸렌(Acenaphthylene), 아세나프텐(Acenaphthene), 플루오렌(Fluorene), 플루오란텐(fluoranthene), 피렌(Pyrene), 크리센(Chrysene), 벤조피렌(Benzopyrene)을 600ppm 함유하는 용액(pH 11)에 2시간 동안 담지한 후 상온에서 건조하였다.600 ppm of Naphtalene, Acenaphthylene, Acenaphthene, Fluorene, Fluorene, Pyrene, Chrysene, and Benzopyrene after washing It was dipped in a solution (pH 11) for 2 hours and dried at room temperature.
실시예 1 내지 4추출물을 50 mg/L 농도로 시편에 처리하고 3시간 동안 반응시켰으며, 대조군은 PBS를 도포하고 3시간 동안 반응시켰다.Examples 1 to 4 extracts were treated with the specimens at a concentration of 50 mg / L and reacted for 3 hours, and the control group was coated with PBS and reacted for 3 hours.
PBS로 세척한 후 시편을 일정 중량으로 절단하고 호모게나이저로 분쇄하였다. 분쇄된 조직을 anhydrous sodium sulfate(Na2SO4)으로 건조시킨 후 속실렛 추출(Sohxlet extraction) 및 액액 추출(Liquid-liquid extraction) 방법을 통해 조직 내 다환방향족탄화수소를 추출하였고(Husain et al., 1997; Takatsuki et al., 1985), HPLC로 정량하였다. 평가 결과는 실험군 대비 대조군의 비율로 나타내었으며, 정량 결과는 하기 표 13과 같다.After washing with PBS, the specimen was cut to a certain weight and ground with a homogenizer. The pulverized tissue was dried with anhydrous sodium sulfate (Na 2 SO 4 ) and then polycyclic aromatic hydrocarbons were extracted from the tissue by Soxlet extraction and Liquid-liquid extraction (Husain et al., 1997; Takatsuki et al., 1985), quantified by HPLC. Evaluation results were expressed as the ratio of the control group to the experimental group, the quantitative results are shown in Table 13.
[% of control][% of control]
구분division 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4
나프탈렌naphthalene 7.17.1 5.55.5 4.74.7 3.43.4
아세나프틸렌Acenaphthylene 10.510.5 8.28.2 6.46.4 5.15.1
플루오렌Fluorene 9.39.3 7.37.3 5.15.1 2.82.8
플루오란텐Fluoranthene 9.39.3 6.96.9 4.54.5 3.23.2
피렌Pyren 3.63.6 2.52.5 1.91.9 1.81.8
크리센Krissen 4.94.9 3.93.9 2.32.3 1.31.3
벤조피렌Benzopyrene 3.13.1 2.72.7 2.22.2 1.31.3
표 13을 참조하면, 상기 다환방향족탄화수소는 실시예 1 내지 4의 추출물의 처리에 의해 현저히 감소되었으며, 상기 결과는 상기 추출물이 미세먼지 및 대기 중 다량 함유되어 피부에 트러블을 야기할 수 있는 유해물질을 효과적으로 제거할 수 있음을 시사한다.Referring to Table 13, the polycyclic aromatic hydrocarbons were significantly reduced by the treatment of the extracts of Examples 1 to 4, and the results indicate that the extract contains a large amount of fine dust and air, which may cause trouble to the skin. It can be effectively removed.
실험예 10 : 미세먼지 제거 효과 시험Experimental Example 10: fine dust removal effect test
실시예 1 내지 4를 제형화한 화장료 조성물의 미세먼지 제거 효과를 시험하였다. PM2.5 내지 PM10 크기에 해당하는 미세먼지를 인공 피부에 도포한 후, 실시예 1 내지 4를 제형화한 클렌징 크림을 이용하여 세척하였다.The fine dust removal effect of the cosmetic composition which formulated Examples 1-4 was tested. After applying the fine dust corresponding to the PM2.5 to PM10 size to the artificial skin, it was washed using a cleansing cream formulated Examples 1 to 4.
상기 클렌징 크림 세척 전후의 미세먼지 비율을 계산하였으며 대조군으로 실시예 1 내지 4의 추출물을 포함하지 않는 클렌징 크림을 사용하였다. 평가 결과는 하기 표 14와 같다.The percentage of fine dust before and after the cleansing cream was washed and a cleansing cream containing no extracts of Examples 1 to 4 was used as a control. The evaluation results are shown in Table 14 below.
구분division 미세먼지 제거율(%)Fine dust removal rate (%)
실시예 1Example 1 92%92%
실시예 2Example 2 93%93%
실시예 3Example 3 93%93%
실시예 4Example 4 96%96%
대조군Control 76%76%
표 14를 참조하면, 미세먼지는 실시예 1 내지 4의 추출물을 제형화한 클렌징 크림에 의해 효과적으로 제거된 반면, 상기 추출물을 함유하지 않는 대조군의 미세먼지 제거 효과는 상대적으로 미흡하였다.Referring to Table 14, the fine dust was effectively removed by the cleansing cream formulated with the extracts of Examples 1 to 4, while the fine dust removal effect of the control containing no extract was relatively insufficient.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.The foregoing description of the present invention is intended for illustration, and it will be understood by those skilled in the art that the present invention may be easily modified in other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the invention is indicated by the following claims, and it should be construed that all changes or modifications derived from the meaning and scope of the claims and their equivalents are included in the scope of the invention.

Claims (7)

  1. 부레옥잠(Eichhornia crassipes) 추출물을 유효성분으로 포함하는 미세먼지 흡착용 화장료 조성물.Water hyacinth ( Eichhornia) crassipes ) Cosmetic composition for adsorption of fine dust comprising the extract as an active ingredient.
  2. 제1항에 있어서,The method of claim 1,
    상기 부레옥잠 추출물은 발효 균주를 접종하여 제조된 발효 추출물인 화장료 조성물.The water hyacinth extract is a cosmetic composition is a fermentation extract prepared by inoculating fermentation strain.
  3. 제2항에 있어서,The method of claim 2,
    상기 발효 균주는 락토바실러스 김치쿠스(Lactobacillus kimchicus)인 화장료 조성물.The fermentation strain is Lactobacillus kimchicus cosmetic composition ( Lactobacillus kimchicus ).
  4. 제1항에 있어서,The method of claim 1,
    상기 추출물은 물, 탄소수 1 내지 4개의 무수 또는 함수 저급 알코올, 아세톤, 석유에테르, 에틸아세테이트, 부틸아세테이트, 트리클로로메탄, 디클로로메탄, 클로로포름, 헥산 및 1,3-부틸렌글리콜로 구성된 군으로부터 선택되는 하나 이상의 용매로 추출된 화장료 조성물.The extract is selected from the group consisting of water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms, acetone, petroleum ether, ethyl acetate, butyl acetate, trichloromethane, dichloromethane, chloroform, hexane and 1,3-butylene glycol Cosmetic composition extracted with one or more solvents.
  5. 제4항에 있어서,The method of claim 4, wherein
    상기 알코올은 65 내지 75% 농도(v/v)의 에탄올인 화장료 조성물.The alcohol is a cosmetic composition of 65 to 75% concentration (v / v) ethanol.
  6. 제1항 내지 제5항 중 어느 한 항에 있어서,The method according to any one of claims 1 to 5,
    유연화장수, 영양화장수, 수분크림, 영양크림, 마사지크림, 에센스, 앰플, 젤, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나 이상으로 제형화된 화장료 조성물.Cosmetics formulated with one or more selected from the group consisting of softening cream, nourishing cream, moisture cream, nourishing cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and powder Composition.
  7. 부레옥잠(Eichhornia crassipes) 추출물을 유효성분으로 포함하는 항산화, 항염증, 피부 보습, 또는 주름 개선용 화장료 조성물.Water hyacinth ( Eichhornia) Crassipes ) Cosmetic composition for antioxidant, anti-inflammatory, skin moisturizing, or wrinkle improvement comprising the extract as an active ingredient.
PCT/KR2016/014621 2016-12-08 2016-12-14 Cosmetic composition containing eichhornia crassipes extract as active ingredient WO2018105799A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680091346.4A CN110022854B (en) 2016-12-08 2016-12-14 Cosmetic composition containing Eichhornia crassipes extract as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0167061 2016-12-08
KR1020160167061A KR101917740B1 (en) 2016-12-08 2016-12-08 Cosmetic compositon containing extracts of water hyacinth

Publications (1)

Publication Number Publication Date
WO2018105799A1 true WO2018105799A1 (en) 2018-06-14

Family

ID=62491076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/014621 WO2018105799A1 (en) 2016-12-08 2016-12-14 Cosmetic composition containing eichhornia crassipes extract as active ingredient

Country Status (3)

Country Link
KR (1) KR101917740B1 (en)
CN (1) CN110022854B (en)
WO (1) WO2018105799A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102248056B1 (en) * 2018-11-28 2021-05-03 황준환 Cosmetic Composition containing Bottle Gourd Extract and Manufacturing method of thereof
KR102085513B1 (en) 2019-02-11 2020-03-05 주식회사 래디안 Cosmetic composition containing extract of basil seed, and mask pack and manufacturing method of mask pack using the same
KR102277577B1 (en) * 2019-11-07 2021-07-15 제주대학교 산학협력단 Composition comprising fucosterol for protecting skin against particulate matter

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013696A1 (en) * 2000-05-18 2004-01-22 Daniel Duche Use of ellagic acid as an anti-pollution cosmetic agent
US20080044373A1 (en) * 2006-06-13 2008-02-21 L'oreal Cosmetic composition for the lips, combining a phosphate surfactant and a silicone polymer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809003B1 (en) * 2000-05-18 2003-01-24 Oreal ANTI-POLLUTION COMPOSITIONS BASED ON ANTHOCYANES
FR2809012A1 (en) * 2000-05-18 2001-11-23 Oreal Cosmetic anti-pollution or depollution agent useful for protecting skin or hair against heavy metal-induced damage, comprises cell extract of plant of the Pontedericaceae family, preferably water hyacinth
KR20110101868A (en) * 2010-03-10 2011-09-16 한방바이오 주식회사 Lactobacillus strains for the bioconversion of ginseng saponins and a saponin bioconversion method using the same
FR3003170A1 (en) * 2013-03-15 2014-09-19 Rech Cosmetique S A R L Soc D USE OF AN EXTRACT OF WATER JACINTHE FOR MOISTURIZING THE SKIN
CN104274377A (en) * 2013-07-11 2015-01-14 青岛道合生物科技有限公司 Eichhornia crassipes body wash for young girls
CN104367499A (en) * 2013-08-16 2015-02-25 青岛道合生物科技有限公司 Water hyacinth refreshing bath lotion
FR3012963B1 (en) * 2013-11-12 2015-12-11 Rech Cosmetique S A R L Soc D OILY COMPOSITION BASED ON LIPOPHILIC EXTRACTS OF PORCELAIN ROSE AND WATER JACINTH.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013696A1 (en) * 2000-05-18 2004-01-22 Daniel Duche Use of ellagic acid as an anti-pollution cosmetic agent
US20080044373A1 (en) * 2006-06-13 2008-02-21 L'oreal Cosmetic composition for the lips, combining a phosphate surfactant and a silicone polymer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"LACTOBACILLUS/WATER HYACINTH FERMENT", CAFE.DAUM.NET, 23 March 2012 (2012-03-23), pages 1, Retrieved from the Internet <URL:http://cafe.daum.net/_c21_/bbs_search_read?grpid=1Kcli&fldid=cbg0&datanum=172&q-ferment&_referer=V7kfJwkeLEGMZxGlgqZEmSsw1QJT8676jJOL2vEDy_oO> *
"Lactobacillus/Water Hyacinth Ferment", COSDNA.COM, 28 January 2012 (2012-01-28), pages 1, Retrieved from the Internet <URL:http://www.cosdna.com/eng/ef5f9d14238.html> *
JULLIHAR R. ET AL.: "Production of Lactic Acid from Water Hyacinth by Lactobacillus spp.", KOREAN SOCIETY FOR BIOTECHNOLOGY AND BIOENGINEERING JOURNAL, vol. 31, no. 1, 22 March 2016 (2016-03-22), pages 85 - 89, XP055513568 *

Also Published As

Publication number Publication date
CN110022854A (en) 2019-07-16
CN110022854B (en) 2022-02-11
KR20180065789A (en) 2018-06-18
KR101917740B1 (en) 2018-11-13

Similar Documents

Publication Publication Date Title
WO2013032189A9 (en) Fermented vegetable oil and composition including same
WO2017026855A1 (en) Composition for improving skin condition containing exopolysaccharide produced by ceriporia lacerata as active ingredient
WO2018105799A1 (en) Cosmetic composition containing eichhornia crassipes extract as active ingredient
WO2020040407A1 (en) Novel cutibacterium avidum strain, and composition for preventing or treating atopic dermatitis, comprising strain or cultured product thereof
WO2020222472A1 (en) Cosmetic composition comprising culture solution of mesenchymal stem cells cultured in hpl-containing medium
WO2022050559A1 (en) Method for preparing deinoxanthin fermented extract and cosmetic composition comprising deinoxanthin fermented extract
WO2019004738A2 (en) Use of composition comprising adipose stem cell-derived exosome as effective ingredient in alleviating dermatitis
WO2018004224A2 (en) Novel sporichthyaceae microorganism and use thereof
WO2023085612A1 (en) Method for producing fermented caviar oil using skin flora, and cosmetic composition comprising same
WO2022131613A1 (en) Cosmetic composition containing mixture of rosmarinic acid and lemon balm leaf extract as active ingredient
KR20190088156A (en) Pearl shell mucus filtrate showing anti-aging, anti-oxidative, anti-inflammatory and anti-wrinkle, manufacturing method thereof and cosmetic compositions comprising the same
WO2019013396A1 (en) Cosmetic composition containing hippophae rhamnoides fruit extract for whitening emulsion and method for manufacturing same
WO2014065446A1 (en) Slimming composition for fat decomposition by caffeine and paraxanthine
WO2016045714A1 (en) Solute and solute mixture, and a composition containing at least one solute, for use in the prevention or treatment of cosmetic or pathological efflorescences caused by particulate matter
WO2024136533A1 (en) Cosmetic composition containing low molecular weight anionic peptide isolated from citrus junos seed
WO2023277367A1 (en) Cosmetic composition comprising antarctic microorganism culture medium
WO2013109096A1 (en) Method for preparing 3,6-anhydro-l-galactose, and use thereof
WO2018216941A1 (en) Hydrogenated mel derived from pseudoz y ma genus strains and use thereof
WO2017074009A1 (en) Antiaging cosmetic composition containing keratin peptides as active ingredient
WO2021045520A1 (en) Cosmetic composition comprising fibroblast growth factor 17
WO2021091284A2 (en) Cosmetic composition for preventing skin aging and reducing skin wrinkles, comprising viburnum stellato-tomentosum extract
WO2016017894A1 (en) Cosmetic composition containing upland rice extract and method for preparing same
WO2017138692A1 (en) Cosmetic composition for skin improvement, containing extract of nymphoides sp. plant
WO2019190010A1 (en) Ethanol extraction composition of citri unshius pericarpium, magnolia officinalis, corydalis remota, and acacia catechu, having effects of skin wrinkle amelioration, moisturization, antioxidation, or inflammation reduction
WO2024158103A1 (en) Composition containing streptococcus sp. strain for prevention, alleviation, or treatment of skin diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16923233

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23.09.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 16923233

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载